Pix by Proximity has been introduced by the Central bank of Brazil,...

Austria-based payment brand Bluecode has announced the launch...

Boxo has partnered with global payments infrastructure firm

Nepal Clearing House Limited (NCHL) and

Canada-based financial institution TD Bank Group (TD) has...

Everest Bank has...

Emirates NBD and...

US-based fintech Felix Pago has announced a partnership...

Lithuania-based iDenfy has introduced an AI-powered Data Crossmatch feature aimed at improving the Know Your Business (KYB) compliance process.

Saudi Arabia-based fintech infrastructure platform Lean Technologies has raised USD 67.5 million in a Series B funding round to scale its Pay-by-Bank and Open Banking offerings.

Mastercard has entered into a partnership with Tap Payments to launch a Click to Pay with Payment Passkey service for optimised ecommerce transactions. 

SEB Embedded has selected Thought Machine’s cloud-native core banking system, Vault Core, as the foundation for its latest service offering.

Metro Bank has been fined nearly GBP 17 million by the UK’s financial watchdog FCA for failings in its money-laundering controls over four years.

The National Bank of Cambodia (NBC) has announced the launch of the Bakong Tourists App with Mastercard, with the institution aiming to optimise digital payments for tourists visiting Cambodia. 

Singapore-based TransferTo has partnered with the Pan-African Ecobank Group in order to expand financial access and cross-border payments across the region of Africa.

The graphics in my post about R^2 were produced by an updated version of a sixty-year old program involving the U.S. census. Originally, the program was based on census data from 1900 to 1960 and sought to predict the population in 1970. The software back then was written in Fortran, the predominate technical programming language a half century ago. I have updated the MATLAB version of the program so that it now uses census data from 1900 to 2020.... read more >>

Our technical support group recently received a request for a tool that would convert IBM System/360 hexadecimal floating point numbers to the IEEE-754 format. I am probably the only one left at MathWorks that actually used IBM mainframe computers. I thought we had seen the last of hexadecimal arithmetic years ago. But, it turns out that the hexadecimal floating point format is alive and well.... read more >>

Floating point arithmetic doesn't get the respect it deserves. Many people consider it mysterious, fuzzy, unpredictable. These misgivings often occur in discussion of vector sums. Our provocatively named SuperSum is intended to calm these fears.... read more >>

A few days ago, a bug report from our office in Cambridge caught my attention. Computing the singular values and singular vectors of a particular matrix would sometimes cause MATLAB to crash.... read more >>

The NA-Digest is an electronic newsletter for the numerical analysis and scientific software community. The NA-Digest is one of world's first examples of social networking. The Digest is one of the forces that makes our community a living, viable community.... read more >>

I didn't know anything about these topics until a couple of weeks ago. Now I can't stop thinking about them.... read more >>

Shortly after I posted Redheffer, Mertens and One-Million Dollars a few days ago, Mathworks' Pat Quillen made an important observation about computing the Mertens function.... read more >>

Shortly after I published the second post about the Mertens conjecture, a reader's comment suggested a new approach to computing Redheffer determinants and the Mertens function. It is now possible to compute a half-million values of the Mertens function in about five hours.... read more >>

Recently, I have made a series of blog posts about Redheffer matrices and the Mertens conjecture. After each of the posts, readers and colleagues offered suggestions to speed up the calculations. Here is a summary of what I have learned.... read more >>

Source: Bryce Adams 11/04/2024

O3 Mining Inc. (TSXV:OIII; OTCQX:OIIIF) updated the timeline for its flagship Marban Alliance gold project in Quebec and closed a small equity financing, reported CIBC analyst Bryce Adams in an Oct. 30 research note.

"With the updated shareholder register and continued derisking of Marban, we expect that the takeout potential for O3 shares increases within the next two years," Adams wrote.

O3 Mining is the third iteration of the successful Osisko Mining Inc. (OSK:TSX) model, focused on acquiring, exploring and developing mineral properties in Canada.

168% Return Implied

The Canadian company was trading at the time of the report at about CA$1.12 per share, and CIBC's target price on it is CA$3 per share, noted Adams. These figures reflect a potential return for investors of 168%.

O3 Mining has an Outperformer rating.

PEA Coming this Quarter

Adams presented O3's timeline for Marban Alliance and noted it aligns with CIBC's projections. The next step is completion of a preliminary economic assessment (PEA), slated for Q4/24, "which we expect will be reported on a standalone basis, with upside from potential toll milling agreements," the analyst wrote. G Mining Services now is the lead consultant on the PEA.

Next, a feasibility study will be done based on the PEA and the 2022 prefeasibility study. Targeted dates are Q1/25 to start it and Q2/25 to finish it.

Also in Q1/25, baseline environmental studies are slated for completion. Impact studies are to be started in Q2/25, and filing is slated for Q1/26.

More Strategic Investments

O3 Mining completed a non-brokered private placement of CA$1.4 million with Sidex LP and NQ Investissement Minier, two mining investment funds sponsored by the Quebec government, reported Adams. Subsequently, O3 closed a follow-up offering of US$76,800 to the company's strategic investor at the same terms.

"We view these as smaller issuances, and after model updates, our net asset value per share estimate is now one penny lower at CA$4.48 per share," Adams wrote.

O3 Mining will use the proceeds to drill at Kinebik, where it continues to consolidate land. This project shares the same formation as Hecla Mining Co.'s (HL:NYSE) Casa Berardi mine and Gold Fields Ltd.'s (GFI:NYSE; GFI:JSE) Windfall project.

Takeout Target Potential

Through its acquisition of Osisko, Gold Fields gained 100% ownership of Windfall (it previously had acquired 50% from Osisko in 2023) and 17% of O3 Mining, Adams pointed out. Gold Fields also unsuccessfully made a bid for Yamana Gold Inc.'s (YRI:TSX; AUY:NYSE; YAU:LSE) interests in the Canadian Malartic mine in Quebec earlier in 2023 and "has indicated further growth interest in Quebec."

"With Measured and Indicated resources of 2,400,000 ounces (2.4 Moz) and Inferred resources of 0.6 Moz at its flagship Marban project and near-term final permitting submission, O3 has above average takeout potential," purported Adams.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. O3 Miing Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for CIBC Equity Research, O3 Mining Inc., October 30, 2024

Analyst Certification: Each CIBC World Markets Inc. research analyst named on the front page of this research report, or at the beginning of any subsection hereof, hereby certifies that (i) the recommendations and opinions expressed herein accurately reflect such research analyst's personal views about the company and securities that are the subject of this report and all other companies and securities mentioned in this report that are covered by such research analyst and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by such research analyst in this report.

Potential Conflicts of Interest: Equity research analysts employed by CIBC World Markets Inc. are compensated from revenues generated by various CIBC World Markets Inc. businesses, including the CIBC World Markets Investment Banking Department. Research analysts do not receive compensation based upon revenues from specific investment banking transactions. CIBC World Markets Inc. generally prohibits any research analyst and any member of his or her household from executing trades in the securities of a company that such research analyst covers. Additionally, CIBC World Markets Inc. generally prohibits any research analyst from serving as an officer, director or advisory board member of a company that such analyst covers. In addition to 1% ownership positions in covered companies that are required to be specifically disclosed in this report, CIBC World Markets Inc. may have a long position of less than 1% or a short position or deal as principal in the securities discussed herein, related securities or in options, futures or other derivative instruments based thereon. Recipients of this report are advised that any or all of the foregoing arrangements, as well as more specific disclosures set forth below, may at times give rise to potential conflicts of interest. CIBC World Markets Inc. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that CIBC World Markets Inc. may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Analysts employed outside the U.S. are not registered as research analysts with FINRA. These analysts may not be associated persons of CIBC World Markets Corp. and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

CIBC World Markets Inc. Price Chart For price and performance charts, please visit CIBC on the web at https://researchcentral.cibccm.com/#/disclaimer-centralnew or write to CIBC World Markets Inc., 161 Bay Street, 4th Floor, Toronto, ON M5H 2S8, Attn: Research Disclosure Chart Request.

Important Disclosure Footnotes for O3 Mining Inc. (OIII.V) • 2a These companies are clients for which a CIBC World Markets company has performed investment banking services in the past 12 months: O3 Mining Inc. • 2c CIBC World Markets Inc. has managed or co-managed a public offering of securities for these companies in the past 12 months: O3 Mining Inc. • 2e CIBC World Markets Inc. has received compensation for investment banking services from these companies in the past 12 months: O3 Mining Inc. • 2g CIBC World Markets Inc. expects to receive or intends to seek compensation for investment banking services from these companies in the next 3 months: O3 Mining Inc. • 3a These companies are clients for which a CIBC World Markets company has performed non-investment banking, securities-related services in the past 12 months: O3 Mining Inc. For important disclosure footnotes for companies mentioned in this report that are covered by CIBC World Markets Inc., click here: CIBC Disclaimers & Disclosures

Legal Disclaimer This report is issued by CIBC Capital Markets. CIBC Capital Markets is a trademark brand name under which Canadian Imperial Bank of Commerce (“CIBC”), its subsidiaries and affiliates (including, without limitation, CIBC World Markets Inc., CIBC World Markets Corp. and CIBC Capital Markets (Europe) S.A.) provide different products and services to our customers around the world. Products and/or services offered by CIBC include corporate lending services, foreign exchange, money market instruments, structured notes, interest rate products and OTC derivatives. CIBC’s Foreign Exchange Disclosure Statement relating to guidelines contained in the FX Global Code can be found at https://cibccm.com/en/disclosures/fx-disclosure-statement/. Other products and services, such as exchange-traded equity and equity options, fixed income securities and futures execution of Canadian securities, are offered through directly or indirectly held subsidiaries of CIBC as indicated below. CIBC World Markets Inc. is a member of the Canadian Investor Protection Fund and the Canadian Investment Regulatory Organization. In the United States, CIBC World Markets Corp. is a member of the Financial Industry Regulatory Authority and the Securities Investor Protection Fund. In Luxembourg. CIBC Capital Markets (Europe) S.A. (RCS Luxembourg: B236326) is authorised by the European Central Bank (the “ECB”) and supervised by the Luxembourg Financial Supervisory Authority (Commission de Surveillance du Secteur Financier) under the oversight of the ECB. CIBC Australia Ltd (AFSL No: 240603) is regulated by the Australian Securities and Investment Commission (“ASIC”). CIBC World Markets (Japan) Inc. is a member of the Japanese Securities Dealer Association. CIBC (TSX/NYSE: CM) is a bank chartered under the Bank Act (Canada) having its registered office in Toronto, Ontario, Canada, and regulated by the Office of the Superintendent of Financial Institutions. CIBC New York Branch is licensed and supervised by the New York State Department of Financial Services. In the United Kingdom, CIBC London Branch is authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Canadian Imperial Bank of Commerce, Sydney Branch (ABN: 33 608 235 847) is an authorised foreign bank branch regulated by the Australian Prudential Regulation Authority (APRA). Canadian Imperial Bank of Commerce, Hong Kong Branch is a registered institution under the Securities and Futures Ordinance, Cap 571, and a limited liability foreign company registered with the Hong Kong Companies Registry. Canadian Imperial Bank of Commerce, Singapore Branch is a wholesale bank licensed and regulated by the Monetary Authority of Singapore. This report is issued and approved for distribution by (a) in Canada, CIBC World Markets Inc., a member of the Canadian Investment Regulatory Organization (“CIRO”), the Toronto Stock Exchange, the TSX Venture Exchange and a Member of the Canadian Investor Protection Fund and (b) in the United States either by (i) CIBC World Markets Inc. for distribution only to U.S. Major Institutional Investors (“MII”) (as such term is defined in SEC Rule 15a-6) or (ii) CIBC World Markets Corp., a member of the Financial Industry Regulatory Authority (“FINRA”). U.S. MIIs receiving this report from CIBC World Markets Inc. (the Canadian broker-dealer) are required to effect transactions (other than negotiating their terms) in securities discussed in the report through CIBC World Markets Corp. (the U.S. broker-dealer). CIBC World Markets Corp. accepts responsibility for the content of this research report.

Distribution to Institutional Customers Only Canada This report is provided, for informational purposes only, to institutional investor and retail clients of CIBC World Markets Inc. in Canada, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

Legal Disclaimer (Continued) United States This report is provided, for informational purposes only, to Major US Institutional Investor clients of CIBC World Markets Corp. in the United States, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. United Kingdom The distribution of this report in the United Kingdom is being made only to, or directed only at, persons falling within one or more of the exemptions from the financial promotion regime in section 21 of the UK Financial Services and Markets Act 2000 (as amended) (“FSMA”) including, without limitation, to the following: • authorised firms under FSMA and certain other investment professionals falling within article 19 of the FSMA (Financial Promotion) Order 2005 (“FPO”) and directors, officers and employees acting for such entities in relation to investment; • high value entities falling within article 49 FPO and directors, officers and employees acting for such entities in relation to investment; and • persons who receive this presentation outside the United Kingdom. The distribution of this report to any other person in the United Kingdom is unauthorised and may contravene FSMA. No person falling outside such categories should treat this report as constituting a promotion to them or rely or act on it for any purposes whatsoever. This report is distributed solely to eligible counterparties or professional clients and not retail clients as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. All other jurisdictions This report is distributed solely to institutional clients and not retail clients as defined by the applicable securities legislation and regulation to which CIBC Capital Markets may be subject in any jurisdiction, and only in compliance with all applicable laws and regulations. The securities mentioned in this report may not be suitable for all types of investors. This report does not take into account the investment objectives, financial situation or specific needs of any particular client of CIBC World Markets. Recipients should consider this report as only a single factor in making an investment decision and should not rely solely on investment recommendations contained herein, if any, as a substitution for the exercise of independent judgment of the merits and risks of investments. The analyst writing the report is not a person or company with actual, implied or apparent authority to act on behalf of any issuer mentioned in the report. Before making an investment decision with respect to any security recommended in this report, the recipient should consider whether such recommendation is appropriate given the recipient's particular investment needs, objectives and financial circumstances. CIBC World Markets suggests that, prior to acting on any of the recommendations herein, Canadian retail clients of CIBC World Markets contact one of our client advisers in your jurisdiction to discuss your particular circumstances. Non-client recipients of this report who are not institutional investor clients of CIBC World Markets should consult with an independent financial advisor prior to making any investment decision based on this report or for any necessary explanation of its contents. CIBC World Markets will not treat non-client recipients as its clients solely by virtue of their receiving this report

Legal Disclaimer (Continued) Past performance is not a guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance of any security mentioned in this report. The price of the securities mentioned in this report and the income they produce may fluctuate and/or be adversely affected by exchange rates, and investors may realize losses on investments in such securities, including the loss of investment principal. CIBC World Markets accepts no liability for any loss arising from the use of information contained in this report, except to the extent that liability may arise under specific statutes or regulations applicable to CIBC World Markets. Information, opinions and statistical data contained in this report were obtained or derived from sources believed to be reliable, but CIBC World Markets does not represent that any such information, opinion or statistical data is accurate or complete (with the exception of information contained in the Important Disclosures section of this report provided by CIBC World Markets or individual research analysts), and they should not be relied upon as such. All estimates, opinions and recommendations expressed herein constitute judgments as of the date of this report and are subject to change without notice. Nothing in this report constitutes legal, accounting or tax advice. Since the levels and bases of taxation can change, any reference in this report to the impact of taxation should not be construed as offering tax advice on the tax consequences of investments. As with any investment having potential tax implications, clients should consult with their own independent tax adviser. This report may provide addresses of, or contain hyperlinks to, Internet web sites. CIBC World Markets has not reviewed the linked Internet web site of any third party and takes no responsibility for the contents thereof. Each such address or hyperlink is provided solely for the recipient's convenience and information, and the content of linked third party web sites is not in any way incorporated into this document. Recipients who choose to access such third-party web sites or follow such hyperlinks do so at their own risk. Although each company issuing this report is a wholly owned subsidiary of CIBC, each is solely responsible for its contractual obligations and commitments, and any securities products offered or recommended to or purchased or sold in any client accounts (i) will not be insured by the Federal Deposit Insurance Corporation (“FDIC”), the Canada Deposit Insurance Corporation or other similar deposit insurance, (ii) will not be deposits or other obligations of CIBC, (iii) will not be endorsed or guaranteed by CIBC, and (iv) will be subject to investment risks, including possible loss of the principal invested. CIBC Capital Markets and the CIBC Logo Design are trademarks of CIBC, used under license. © 2024 CIBC World Markets Inc., CIBC World Markets Corp. and CIBC Capital Markets (Europe) S.A. All rights reserved. Unauthorised use, distribution, duplication or disclosure without the prior written permission of CIBC World Markets is prohibited by law and may result in prosecution.

( Companies Mentioned: TSXV:OIII;OTCQX:OIIIF, )

Source: Jeremy Hoy 11/06/2024

O3 Mining Inc. (TSXV:OIII; OTCQX:OIIIF) announced it now intends to release a completed preliminary economic assessment (PEA) of its Marban Alliance project near Val d'Or in Quebec, Canada, in Q4/24, ahead of the previously planned feasibility study (FS), reported Canaccord Genuity analyst Jeremy Hoy in an Oct. 30 research note.

"Given the time passed since the 2022 prefeasibility study (PFS), moderate inflation, and the run-up in the gold price, we expect to see incremental increases to costs and capex, and likely higher commodity price assumptions for resources in the PEA," Hoy wrote.

Potential Gain of 254%

Canaccord Genuity reiterated its CA$4 per share price target on O3 Mining, trading at the time of the report at about CA$1.13 per share, noted Hoy. From the current price, the return to target is 254%.

The Canadian explorer-developer is a Speculative Buy.

PEA in Progress

Management indicated the PEA will encompass advancements at Marban Alliance made since the PFS, including optimized mining and processing parameters, as well as additional resources, Hoy reported. These additional ounces will come from conversion of resources at the current pits along with the Malartic H zone's 342,000 ounce gold resource.

The PEA and FS will showcase a standalone operation. O3 is evaluating toll milling options separately.

What To Expect, Watch For

Hoy presented the next steps for Marban Alliance, which are potential catalysts for O3 Mining.

Following the completion of the PEA in Q4/24, environmental baseline studies will be finished in Q1/25. The start of impact studies will follow in Q2/25. An FS on the gold project will be done in H2/25. The impact study results will be filed in Q1/26.

Meanwhile, exploration results from Horizon and Kinebik will be released as they become available. Mergers and acquisitions activity is yet another potential stock-moving event.

"O3 is progressing Marban Alliance as a standalone project, but we continue to view [the company] as an important component in any Val d'Or consolidation discussion given its proximity to existing operations and other projects of scale in the region," wrote Hoy.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. O3 Mining Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for Canaccord Genuity, O3 Mining Inc., October 30, 2024

Analyst Certification Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research, and (iii) to the best of the authoring analyst’s knowledge, she/he is not in receipt of material non-public information about the issuer. Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Required Company-Specific Disclosures (as of date of this publication) O3 Mining Inc. currently is, or in the past 12 months was, a client of Canaccord Genuity or its affiliated companies. During this period, Canaccord Genuity or its affiliated companies provided investment banking services to O3 Mining Inc.. In the past 12 months, Canaccord Genuity or its affiliated companies have received compensation for Investment Banking services from O3 Mining Inc. . In the past 12 months, Canaccord Genuity or any of its affiliated companies have been lead manager, co-lead manager or comanager of a public offering of securities of O3 Mining Inc. or any publicly disclosed offer of securities of O3 Mining Inc. or in any related derivatives. Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from O3 Mining Inc. in the next three months. An analyst has visited the material operations of O3 Mining Inc.. Partial payment was received for the related travel costs.

Past performance In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance. Online Disclosures Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@cgf.com. The reader may also obtain a copy of Canaccord Genuity’s policies and procedures regarding the dissemination of research by following the steps outlined above.

General Disclaimers See “Required Company-Specific Disclosures” above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, “Compendium Reports.” “Canaccord Genuity” is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 80%-owned by Canaccord Genuity Group Inc. The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity LLC, a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne. The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research. Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity’s policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity’s policy is available upon request. The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity’s judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability. From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity’s affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research. Research Distribution Policy Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity’s customers who are entitled to receive the firm's research. In addition research may be distributed by the firm’s sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity’s customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent. For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative.

Short-Term Trade Ideas Research Analysts may, from time to time, discuss “short-term trade ideas” in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term ‘Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or “Speculative Buy’ could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity’s research.

For Canadian Residents: This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory. For United States Persons: Canaccord Genuity LLC, a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. For United Kingdom and European Residents: This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority. For Jersey, Guernsey and Isle of Man Residents: This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser. CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc. For Australian Residents: This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052. This report should be read in conjunction with the Financial Services Guide available here - Financial Services Guide. For Hong Kong Residents: This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request. Copyright © Canaccord Genuity Corp. 2024 – Member CIRO/Canadian Investor Protection Fund Copyright © Canaccord Genuity Limited. 2024 – Member LSE, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2024 – Member FINRA/SIPC Copyright © Canaccord Genuity (Australia) Limited. 2024 – Participant of ASX Group, Cboe Australia and of the NSX. Authorized and regulated by ASIC. All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above. None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.

( Companies Mentioned: TSXV:OIII;OTCQX:OIIIF, )

Source: Peter Bell 11/04/2024

Liberty Gold Corp. (LGD:TSX; LGDTF:OTCQX) released the results of the first study, a prefeasibility study (PFS), of its flagship Black Pine project in Idaho, reported Canaccord Genuity analyst Peter Bell in an Oct. 10 research note.

"The completion of the prefeasibility study is a key step in advancing the project through permitting, bringing a Black Pine mine much closer to reality," Bell wrote. "This is positive."

885% Gain Possible

Canaccord Genuity has a CA$3.25 per share price target on the Canadian Idaho-based exploration and development company, trading at the time of the report at about CA$0.33 per share, noted Bell. These figures imply a potential return on investment of 885%.

Liberty is rated Speculative Buy.

Specifics of the PFS

Bell presented the details of the Black Pine operation as outlined in the PFS, based on reserves of 3,110,000 ounces (3.11 Moz) of 0.32 grams per ton (0.32 g/t) gold.

Average production is 183,000 ounces per year (183 Koz/year) gold for the first five years, peaking at about 231 Koz. The average annual production, based on a 50,000 ton per day throughput, over a 17-year life of mine (LOM) is 135 Koz.

The PFS has the head grade during years one through five at 0.45 g/t gold. Over the LOM, the head grade is 0.32 g/t gold and gold recoveries, 70.4%.

As for costs, operating costs are low at US$9.10 per ton processed. The all-in-sustaining cost (AISC) is US$1,205 per ounce (US$1,205/oz) of gold for years one through five and US$1,380/oz of gold for the LOM.

"We believe the study highlights a simple, lower-risk and long-lived operation with an attractive cost profile," Bell wrote. "We model Liberty achieving initial production at Black Pine in 2029, based on company disclosure around the permitting process."

Attractive Economics

Bell reported the economics outlined in the PFS for the base case using a US$2,000/oz gold price. The after-tax net present value discounted at 5% (NPV5%) is US$552 million, the internal rate of return (IRR) is 32%, and the payback period is 3.3 years. The strip ratio is low at 1.3.

"Of note is the study's leverage to higher gold prices with an NPV5% of US$1,296M (62% IRR at US$2,600/oz)," Bell wrote. At the same gold price, Canaccord Genuity's estimated NPV5% is higher, at US$1,569.

Bell noted that Liberty could enhance the value of Black Pine in any of four ways, by optimizing the resource and mine planning; delineating additional ounces or feed sources; using electric, maybe even autonomous, mining equipment; and defining options for using renewable energy like solar to potentially lower operating costs more.

How Results Stack Up

The analysts pointed out the similarities and differences between Liberty Gold's PFS and Canaccord Genuity's estimates on Black Pine. Between the two, the capex, AISC, mined throughput, and NPV are consistent, "which we view as positive," Bell wrote.

Among the parameters that differ are unit costs per ton processed, strip ratio, head grade, recovery, and total recovered ounces, all lower in the PFS. Mine life, though, is longer.

"The longer mine life and lower total ounce total equate to a lower number of ounces of annual production," Bell explained.

Process and general and administrative costs are lower in the PFS, which decreases the cutoff and the overall grade when compared to Canaccord Genuity's version. Bell indicated that the lower operating cost per ton, however, is positive.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Liberty Gold Corp. is a billboard sponsor of Streetwise Reports.
2. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
3. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

Disclosures for Canaccord Genuity, Liberty Gold Corp., October 10, 2024

Analyst Certification Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst’s coverage universe and (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research, and (iii) to the best of the authoring analyst’s knowledge, she/he is not in receipt of material non-public information about the issuer. Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account.

Sector Coverage Individuals identified as “Sector Coverage” cover a subject company’s industry in the identified jurisdiction, but are not authoring analysts of the report. Investment Recommendation Date and time of first dissemination: October 10, 2024, 09:56 ET Date and time of production: October 10, 2024, 09:56 ET Target Price / Valuation Methodology: Liberty Gold Corp. - LGD Our target price is based on a 0.85x multiple applied to our forward curve derived operating NAV less net debt and other corporate adjustments. Risks to achieving Target Price / Valuation: Liberty Gold Corp. - LGD In addition to the usual risks to target prices associated with commodity pricing, exchange rates, and mineral exploration/ development, we highlight the following: Commodity price risk: As a precious metals development company, LGD’s future revenue is dependent on the price of gold. Water rights: The Goldstrike Project does not currently have sufficient water rights to operate the proposed mine and heap leach. They announced June 1 that they have retained consultants to attempt to obtain water. Geo-political risk: Liberty is currently focussed on the western United States but retains exposure to Turkey through the TV-Tower project. Accordingly, Liberty’s operations could be adversely impacted by political or economic instability or changes in government policy that impact the ownership of assets, mining activities, exchange rates, taxation, or royalties in Turkey. We note that Liberty’s Turkish asset, TV-Tower, accounts for less than 3% of NAV in our valuation. Mining risk: LGD faces the typical risks inherent to mining companies relating to operating and capital costs, availability of capital, permitting requirements and timelines, technical and operating parameters, reserve and resource models, social license and community relations, taxation and royalty regimes, and regulatory and political risks. Black Pine does not currently have a published economic study so the estimates in our model are based on our own interpretation of how the operation may be designed. As such, our valuation of the Black Pine project may be impacted by differences in strip ratio, CapEx, mining throughput, recovery assumptions, and gold grade. Development risk: LGD is planning to develop the Black Pine and Goldstrike projects in Idaho and Utah respectively. The company faces risks associated with developing the project including capital and operating cost risk, financing, project permitting and timelines, and technical risks to achieve the planned operating rates. Permitting risk: Permitting is still underway at the Black Pine project. As such, the company may not be able to proceed with the project as it is currently envisaged if the required permits are not received in a timely manner. Financing risk: As a pre-cash-flow development company, LGD is reliant on the capital markets to remain a going concern. At present, the company has an estimated cash position of ~US$13.1M (Q2/24), which positions the company well in the near term to continue to advance its portfolio of exploration/development projects, in our view. We note that there is no guarantee that LGD will be able to access capital markets in the future as the result of potential changes in market sentiment/pricing and/or concerns involving project feasibility. As such, there is no guarantee that LGD will be able to secure the required funds to advance the Black Pine project, including but not limited to debt/equity financing and/or a strategic investment.

Required Company-Specific Disclosures (as of date of this publication) Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Investment Banking services from Liberty Gold Corp. in the next three months.

Past performance In line with Article 44(4)(b), MiFID II Delegated Regulation, we disclose price performance for the preceding five years or the whole period for which the financial instrument has been offered or investment service provided where less than five years. Please note price history refers to actual past performance, and that past performance is not a reliable indicator of future price and/or performance. Online Disclosures Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@cgf.com. The reader may also obtain a copy of Canaccord Genuity’s policies and procedures regarding the dissemination of research by following the steps outlined above.

dissemination of research by following the steps outlined above. General Disclaimers See “Required Company-Specific Disclosures” above for any of the following disclosures required as to companies referred to in this report: manager or co-manager roles; 1% or other ownership; compensation for certain services; types of client relationships; research analyst conflicts; managed/co-managed public offerings in prior periods; directorships; market making in equity securities and related derivatives. For reports identified above as compendium reports, the foregoing required company-specific disclosures can be found in a hyperlink located in the section labeled, “Compendium Reports.” “Canaccord Genuity” is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity LLC, Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 80%-owned by Canaccord Genuity Group Inc. The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity LLC, a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne. The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Investment Banking activities, or to recommendations contained in the research. Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity’s policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity’s policy is available upon request. The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity’s judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability. From time to time, Canaccord Genuity salespeople, traders, and other professionals provide oral or written market commentary or trading strategies to our clients and our principal trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity’s affiliates, principal trading desk, and investing businesses also from time to time make investment decisions that are inconsistent with the recommendations or views expressed in this research. This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

Research Distribution Policy Canaccord Genuity research is posted on the Canaccord Genuity Research Portal and will be available simultaneously for access by all of Canaccord Genuity’s customers who are entitled to receive the firm's research. In addition research may be distributed by the firm’s sales and trading personnel via email, instant message or other electronic means. Customers entitled to receive research may also receive it via third party vendors. Until such time as research is made available to Canaccord Genuity’s customers as described above, Authoring Analysts will not discuss the contents of their research with Sales and Trading or Investment Banking employees without prior compliance consent. For further information about the proprietary model(s) associated with the covered issuer(s) in this research report, clients should contact their local sales representative.

Short-Term Trade Ideas Research Analysts may, from time to time, discuss “short-term trade ideas” in research reports. A short-term trade idea offers a near-term view on how a security may trade, based on market and trading events or catalysts, and the resulting trading opportunity that may be available. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks. A short-term trade idea may differ from the price targets and recommendations in our published research reports that reflect the research analyst's views of the longer-term (i.e. one-year or greater) prospects of the subject company, as a result of the differing time horizons, methodologies and/or other factors. It is possible, for example, that a subject company's common equity that is considered a long-term ‘Hold' or 'Sell' might present a short-term buying opportunity as a result of temporary selling pressure in the market or for other reasons described in the research report; conversely, a subject company's stock rated a long-term 'Buy' or “Speculative Buy’ could be considered susceptible to a downward price correction, or other factors may exist that lead the research analyst to suggest a sale over the short-term. Short-term trade ideas are not ratings, nor are they part of any ratings system, and the firm does not intend, and does not undertake any obligation, to maintain or update short-term trade ideas. Short-term trade ideas are not suitable for all investors and are not tailored to individual investor circumstances and objectives, and investors should make their own independent decisions regarding any securities or strategies discussed herein. Please contact your salesperson for more information regarding Canaccord Genuity’s research.

For Canadian Residents: This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory. For United States Persons: Canaccord Genuity LLC, a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity LLC. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity LLC and therefore may not be subject to the FINRA Rule 2241 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. For United Kingdom and European Residents: This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority. For Jersey, Guernsey and Isle of Man Residents: This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser. CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc. For Australian Residents: This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited or its Wealth Management affiliated company, Canaccord Genuity Financial Limited ABN 69 008 896 311 holder of AFS Licence No 239052. This report should be read in conjunction with the Financial Services Guide available here - Financial Services Guide. For Hong Kong Residents: This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request. Copyright © Canaccord Genuity Corp. 2024 – Member CIRO/Canadian Investor Protection Fund Copyright © Canaccord Genuity Limited. 2024 – Member LSE, authorized and regulated by the Financial Conduct Authority. Copyright © Canaccord Genuity LLC 2024 – Member FINRA/SIPC

Copyright © Canaccord Genuity (Australia) Limited. 2024 – Participant of ASX Group, Cboe Australia and of the NSX. Authorized and regulated by ASIC. All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity Corp., Canaccord Genuity Limited, Canaccord Genuity LLC or Canaccord Genuity Group Inc. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above. None of the material, nor its content, nor any copy of it, may be altered in any way, reproduced, or distributed to any other party including by way of any form of social media, without the prior express written permission of the entities listed above.

( Companies Mentioned: LGD:TSX; LGDTF:OTCQX, )

Source: Streetwise Reports 11/05/2024

Dolly Varden Silver Corp. (DV:TSX.V; DOLLF:OTCQX) released results from five drill holes from its completed 2024 drilling program at its Kitsault Valley project in British Columbia's Golden Triangle.

In total, the program drilled 69 holes for 31,726 meters — 41 holes totaling more than 15,000 meters at the Dolly Varden area and 28 holes totaling more than 16,000 meters at Homestake Ridge.

Highlights of Monday's release include one hole from the Homestake Silver Deposit that found 12.23 grams per tonne gold (g/t Au) and 84 g/t silver (Ag) over 34.93 meters with high-grade breccia veins that included 166 g/t Au and 675 g/t Ag over 0.97 meters.

"The identification of a gold-rich, wide and high-grade area within the Homestake Silver Deposit is highly encouraging," said Chief Executive Officer Shawn Khunkhun. "Our geological team is encouraged by overlapping mineralizing phases of silver and gold-rich veins and breccias; the deposit remains open for expansion."

Technical Analyst Clive Maund, writing on Sunday, called Dolly Varden "one of the best pure silver companies around."

The stock's "breakout at end of last month/early this month was on big volume means it was genuine," Maund wrote.

The stock is at a "classic buy spot, although we should remain aware that it could zigzag a little lower over the short-term, but that said it looks like a strong buy here."

Highlights From Results

Highlights from the Homestake Silver Deposit include:

• Hole HR24-432: Mineralized envelope including veins: 8.85 g/t Au and 5 g/t Ag over 48.23 meters, including an internal zone of stronger breccia vein intervals grading 29.24 g/t Au and 16 g/t Ag over 13.94 meters, including one breccia vein grading 701 g/t Au and 184 g/t Ag over 0.54 meters.
• Hole HR24-435: Mineralized envelope including veins: 4.64 g/t Au and 38 g/t Ag over 100.80 meters, including an internal interval of stronger breccia vein mineralization grading 12.23 g/t Au and 84 g/t Ag over 34.93 meters. High-grade breccia veins include 166 g/t Au and 675 g/t Ag over 0.97 meters.
• Hole HR24-442: Vein breccia zone: 4.58 g/t Au over 9.95 meters, including 14.96 g/t Au over 1.69 meters.

"Results from the five holes in this release suggest that the plunge of mineralization at Homestake Silver has a similar orientation as the Homestake Main Deposit, located 300 meters to the northwest," the company said in a release. "The average grades within these core areas are higher, on a precious metal silver equivalent basis, than the average grade of the silver deposits at the Dolly Varden property further south, due to the increased gold content at the Homestake Ridge Deposits."

Technical Analyst Clive Maund, writing on Sunday, called Dolly Varden "one of the best pure silver companies around."

Drill holes HR24-442 and HR24-445 are step-outs and encountered the mineralized and altered structural corridor of Homestake Silver, the company said. Drill hole HR24-442 intersected a mineralized vein breccia stockwork zone grading 4.58 g/t Au over 9.95 meters, including individual breccias with stronger pyrite mineralization grading 14.96 g/t Au over 1.69 meters.

The Homestake Ridge deposits are interpreted as structurally controlled, multi-phase epithermal vein stockwork and vein breccia system hosted in Jurassic Hazelton volcanic rocks, Dolly Varden noted. Mineralization consists of pyrite plus galena and sphalerite with visible gold in a breccia matrix within a silica breccia vein system.

"The northwest orientation of the main Homestake structural trend appears to have numerous subparallel internal structures that are interpreted to form the controls for higher grade gold and silver shoots within a broader mineralized envelope at the Homestake Silver deposit," the company said. "The main structural corridor dips steeply to the northeast at Homestake Main and rolls to vertical or steeply southwest at Homestake Silver."

Analyst's Response: 'Boom'

Jeff Valks, Senior Analyst for The Gold Advisor newsletter, reacted to the results with the word "BOOM."

"Dolly Varden Silver reports more high-grade drill results from its 2024 exploration program at the Homestake Silver Deposit in British Columbia's Golden Triangle," he wrote on Monday. "Results from five drill holes have confirmed significant gold and silver mineralization in an area targeted within the plunge of a previously undrilled high-grade zone, signaling potential expansion opportunities."

Jeff Valks, Senior Analyst for The Gold Advisor newsletter, reacted to the results with the word "BOOM."

We look forward to the remaining results." Vaks wrote. "In the meantime, the stock is flat as I write but is up over 35% year-to-date. It's not too late to buy, it's down from its recent spike, and as (editor) Jeff (Clark) has said, this is a core holding for the silver bull market. Use a stink bid if you're looking for shares. Both Jeff and I hold long positions."

Analyst Marcus Giannini of Haywood Capital Markets noted in a recent research note that Dolly Varden continues to "push the margins of known high-grade mineralization" at the project.

Gianini gave the stock a Buy rating with a CA$2.40 per share target price. "We continue to view Dolly's high-grade endowment as an increasingly attractive target for larger North American-focused precious metal producers," he noted.

The Catalyst: Analysts Point to Patience

While it has chased the record highs gold has been setting this year, silver recently broke through US$35 per ounce, reflecting a year-to-date gain of about 47%. It has since settled but held to the "crucial US$32.50 level," according to Christopher Lewis of FX Empire on Monday.

"Keep in mind that this is a market that is extraordinarily volatile and, of course, will continue to be noisy over the next couple of days as we get election results in the United States," Lewis wrote. "And of course, we also get the Federal Reserve interest rate decision on Thursday, both of which could cause chaos."

Lewis said he thinks the "least likely path is lower."

"I still favor an upside move, but I recognize that we are definitely in a little bit of a holding pattern," he wrote. "Having said that, if we do see momentum to the upside, then there's really not a whole lot here that could keep this market from trying to challenge the (US$)35 level again, obviously, a large round psychologically significant figure, but we'll just have to wait and see how that plays out."

The most conductive element in nature, silver is used to coat electrical contacts in computers, phones, cars, and appliances. It's also an important element in solar technology.

Mordor Intelligence noted that the white metal is expected to register a compound annual growth rate (CAGR) of more than 5% between 2024 and 2029.

Newsletter editor Brien Lundin encouraged investors not to get discouraged, as any price drop-off is temporary, he said. He expects the silver price to soar when the U.S. Federal Reserve doubles down on its efforts to get interest rates much lower, he wrote on Oct. 23. [OWNERSHIP_CHART-5439]

Based on silver's charts, Ron Struthers of Struthers Resource Stock Report also predicted a major run-up in the silver price.

"Back in April or early May, I highlighted the breakout from a cup and handle formation and [that] that would lead to a major upside move. This is now confirmed," he wrote on Oct. 23.

Ownership and Share Structure

According to the company's latest corporate presentation, 50% of its stock is held by institutional investors, including Fidelity Management & Research Company LLC, Sprott Asset Management LP, U.S. Global Investors Inc., and Delbrook.

About 41% is with strategic investors, including 17% with Fury Gold Mines, 14% with Hecla, and Eric Sprott owns 10% himself.

The rest, 9%, is with retail and high-net-worth investors.

The company has 301.16 million outstanding shares. Its market cap is CA$380.72 million, and its 52-week trading range is CA$0.62–1.46 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Dolly Varden Silver Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Dolly Varden Silver Corp.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: DV:TSX.V; DOLLF:OTCQX, )

Source: Streetwise Reports 11/07/2024

Dakota Gold Corp. (DC:NYSE American) announced drill results from the first 17 holes of its ongoing infill drilling program to expand the maiden resource at its Richmond Hill Gold Project in the historic Homestake District of South Dakota.

An updated S-K 1300 resource estimate is planned for Q1 2025 and a S-K 1300 Initial Assessment with cashflow analysis is planned for Q2 2025, the company said in a release. The expanded resource is expected to include an additional 88 new drill holes totaling 17,000 meters.

"The highlight of this morning's release was (hole) RH24C-099, which was drilled in the Twin Tunnels Zone and returned 1.15 g/t Au (grams per tonne gold) over 51.7 meters from 132.9 meters," wrote Canaccord Genuity Capital Markets Analyst Peter Bell in an updated research note on Monday. "The results this morning were consistent with the current resource at Richmond Hill, with many cases reporting higher-than-average grades."

Bell said the firm was encouraged by the results, "which we believe provide support for expansion in future resource estimates. With infill and step out drilling at Richmond Hill being just one of three ongoing drill programs currently underway at Dakota, underscoring the company's emphasis on exploration and expansion."

Drilling Is 'Adding Ounces'

The maiden S-K 1300 resource, announced in April, outlined an Indicated Resource of 51.83 million tonnes (Mt) at 0.80 g/t Au for 1.33 million ounces (Moz) and Inferred Resource of 58.06 Mt at 0.61 g/t Au for 1.13 Moz., the company said.

The initial infill drill results release released Monday encountered further gold mineralization from the central portion of the Richmond Hill resource area consistent with results reported in the maiden resource, Dakota said. The drilling was conducted in areas where the original resource block model contained gaps to support the company's belief that the initial resource could be significantly expanded with additional infill drilling.

Highlights of the results include:

• Hole RH24C-077: 0.76 g/t Au over 24.4 meters
• Hole RH24C-083: 0.70 g/t Au over 13.8 meters
• Hole RH24C-085: 1.10 g/t Au over 17.9 meters
• Hole RH24C-088A: 0.96 g/t Au over 41.5 meters
• Hole RH24C-099: 1.15 g/t Au over 51.7 meters

Dakota said the resource remained open in all directions and could be improved with more drilling, metallurgical work, and incorporation of silver into the resource.

"We are very pleased to see that initial results from our infill drill program are adding ounces to our current S-K 1300 resource," said Dakota Vice President of Exploration James Berry. "The results to date show grades and widths consistent with drill holes in the original block model and support an expansion of gold mineralization, including shallow oxide mineralization. We look forward to continuing our infill program on the other zones identified in our Initial assessment for follow-up drilling."

'Vastly Unexplored' District

The historic Homestake Mine produced 41 Moz Au and 9 Moz silver (Ag) over 126 years. The company has 48,000 acres of holdings surrounding the original mine, which was first discovered in 1876 and consolidated by George Hearst.

Areas surrounding "super-giant deposits" like Homestake are believed to contain significant additional gold resources, wrote John Newell wrote.

Areas surrounding "super-giant deposits" like Homestake are believed to contain significant additional gold resources, wrote John Newell of John Newell & Associates this week for a Streetwise Reports piece on the legacy of the famous mine.

"Super-giant deposits are characterized by clusters of geologically similar deposits within several hundred square kilometers, defining profoundly mineralized regions," Newell wrote. "It is believed that at least twice that amount of gold exists in the neighborhood of these super giants. If that is true, then there are at least 100 Moz of gold left to be found in this vastly underexplored precious metal district of South Dakota."

This proximity to a super-giant "suggests a high potential for similar deposits," Newell wrote. "Being in the shadow of many old mines increases the probability of finding significant mineral resources."

The Catalyst: Gold Continues Bull Market

After hitting a record high of US$2,790.15 per ounce on Thursday, spot gold was up 0.1% to US$2,737.35 on Monday afternoon, according to Reuters.

Investors were keeping a close on Tuesday's presidential election in the U.S. and the Federal Reserve's meeting later this week, Anjana Anil reported.

"A Reuters/Ipsos poll conducted last month found worries that the U.S. could see a repeat of the unrest that followed Trump's 2020 election defeat, when his false claim that his loss was the result of fraud prompted hundreds to storm the U.S. Capitol," Anil wrote.

Gold's rise has "resulted in big returns for the investors who bought in earlier this year," Angelica Leicht reported for CBS News last month. "For example, the investors who purchased gold in March when it hit US$2,160 per ounce have seen their gold values increase by nearly 27% in the time since. That's a huge uptick in value in a matter of months, especially on an asset that's known more for long-term growth."

Recently polled London Bullion Market Association members indicated they believe the gold price could reach US$2,940/oz during 2025, reported Stockhead on Oct. 28.

"Combined with expectations of lower global interest rates, this further enhances gold's attractiveness as an investment," the article noted.[OWNERSHIP_CHART-7442]

As for gold equities, the S&P/TSX Venture Composite Index (SPCDNX) confirmed a multidecade bull run for junior, intermediate, and senior mining stocks when it closed above 1,000 recently, Stewart Thomson with 321Gold wrote. The index is a key indicator of the health of the general gold, silver, and mining stocks market.

Ownership and Share Structure

According to the company, approximately 25% of its shares are with management and insiders.

Out of management, Co-chairman, Director, President and Chief Executive Officer Robert Quartermain holds the most shares at 8.4%, while COO Jerry Aberle holds 4.8%, the company said.

About 26% of the shares are with institutional investors, according to Yahoo Finance and Edgar filings. Top institutional holders include Fourth Sail Capital with 5.3%, Van Eck Associates with 4.1%, Blackrock Institutional Trust Co. with 3.7%, The Vanguard Group Inc. with about 3.2%, Fidelity Management and Research Co. LLC with 2.7%, and CI Global Asset Management with 2.6%.

About 16.5% is with strategic investors, including Orion Mine Finance, which owns about 9.9%, and Barrick Gold Corp., which owns about 2.5%. The rest is retail.

Dakota Gold has a market cap of US$212.61 million, with 93.66 million shares outstanding. It trades in a 52-week range of US$3.25 and US$1.84.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Dakota Gold Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Dakota Gold Corp.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: DC:NYSE American, )

Source: Streetwise Reports 11/06/2024

Golden Cariboo Resources Ltd. (GCC:CSE; GCCFF:OTC; A0RLEP:WKN; 3TZ:FSE) has reported encouraging results from its 2024 field campaign. During the exploration, the company collected 16 rock samples from the Halo zone, North Hixon zone, and Pioneer area. These samples revealed promising gold mineralization in the region. Notable highlights from the Halo zone include grab samples from newly exposed outcrops, with assays reaching 8.47 g/t Au (grams per tonne, gold), 6.59 g/t Au, and 2.39 g/t Au. These samples were taken from altered andesite tuff with quartz-carbonate veins located approximately 101 meters northeast of the nearest drill collar.

Sampling near the Pioneer showing, situated one-kilometer north-northwest of the Halo zone, also returned assays of 1.13 g/t Au and 0.40 g/t Au. The fieldwork's findings have significantly extended the strike length of known gold mineralization by one kilometer and expanded the surface footprint of mineralization to the northeast. Despite challenging glacial cover, Golden Cariboo's team continues to uncover significant gold-bearing outcrops.

The report also underscored the strategic advantages of the property's location, infrastructure, and proximity to Highway 97, which reduces exploration and operational costs. Wortel detailed Golden Cariboo's drilling campaign, which includes results such as Hole QGQ24-013, which intersected 136.51 meters at 1.77 g/t gold, including a higher-grade interval of 23.89 meters at 3.32 g/t gold.

Valuation metrics from the report included a projected fair value of CA$0.40 per share, representing a 74% potential upside from the current trading price of CA$0.23, and doesn't include the added value from recent, significant exploration success. Despite acknowledging the high risks associated with early-stage exploration projects, Couloir Capital emphasized the long-term value potential in a Tier 1 mining jurisdiction, reinforced by the company's experienced management team and promising geological trends.

Frank Callaghan, President and CEO of Golden Cariboo, stated in the news release, "Although there is a lot of glacial cover on this project, our geologists still managed to find new gold-bearing outcrops in areas of great significance. We have now expanded the surface footprint of gold mineralization at the Halo zone to the northeast and increased the strike length of our gold trend. We're in a very large gold system that is being demonstrated by multiple, varied work programs."

Mining and Metals Market

On October 29, Kitco reported that gold prices had reached nearly US$2,800. This price represents a 35% increase for the year. The rise was attributed to multiple factors, including "geopolitical conflicts, Federal Reserve interest rate normalization, continued strong demand from global central banks, and uncertainties about the upcoming presidential election and potential fiscal stimulus." Analysts at Kitco described this combination of elements as a "perfect storm." They noted it had driven investor sentiment and reinforced gold's value as a hedge against economic turmoil.

LiveMint, on October 30, highlighted the substantial returns seen in gold over the past year. Despite this impressive performance, some analysts expressed caution regarding gold's future trajectory. Ajay Kedia, Director of Kedia Advisory, suggested that while gold prices may see a short-term rally, "investors may have to remain cautious on the yellow metal in the second half of 2025." Kedia noted that gold prices could experience profit-taking and a slowdown if interest rate cuts by the Federal Reserve do not materialize as quickly as expected. Nonetheless, gold has continued to serve as a preferred asset for those seeking stability, especially in times of economic and political uncertainty.

In a November 4 report, Egon von Greyerz, Founder and Chairman of Matterhorn Asset Management, provided a historical perspective on gold's role in preserving wealth. Von Greyerz discussed how gold had consistently retained value, even as fiat currencies depreciated over time. He emphasized, "Gold held in the investor's name in safe vaults and jurisdictions outside the financial system is the ultimate form of wealth preservation." Von Greyerz also pointed to gold's outperformance since the 1970s, stating that gold had increased 78 times since President Nixon ended the gold standard in 1971. He argued that gold's journey was "only starting now," citing the ongoing destruction of fiat money value through global debt expansion and monetary policies.

Cariboo Catalysts

According to Golden Cariboo Resources' Q1 2024 investor presentation, the company is advancing exploration on its 3,814-hectare Quesnelle Gold Quartz Mine property, located in British Columbia's historic Cariboo Mining District. The asset benefits from 160 years of mining history and is road-accessible, facilitating year-round exploration. The 2024 exploration program, including trenching and a proposed 2,500-5,000m Phase 2 drilling campaign, aims to delineate the gold system further and complete a National Instrument 43-101 compliant resource estimate.

The property, encircled by Osisko Development Corp. on three sides, holds the potential for high-grade, multi-ounce gold targets. Management is focusing on a multi-phase exploration strategy. This includes trenching to assess shallow overburden and mapping and sampling to refine drill targets. The team's experience and the property's historical and geological significance position Golden Cariboo as a promising exploration venture.

The proposed drilling and development efforts reflect a systematic approach to unlocking value in this underexplored yet historically significant gold camp as the company progresses toward realizing a resource estimate.

Expert Analysis

Golden Cariboo Resources Inc. received favorable coverage from Couloir Capital in a report released on September 3, 2024. Senior Mining Analyst Ron Wortel issued a Buy recommendation for the company, noting the significant potential for discovering a large gold resource at the Quesnelle Gold Quartz property. Wortel highlighted that the property, located in British Columbia's historic Cariboo Mining District, lies along the same geological trend as Osisko Development's projects, suggesting the possibility of tapping into similar high-grade mineralization systems.

The report also underscored the strategic advantages of the property's location, infrastructure, and proximity to Highway 97, which reduces exploration and operational costs. Wortel detailed Golden Cariboo's drilling campaign, pointing out positive early results, such as Hole QGQ24-08, which intersected 263 meters at 0.29 g/t gold, including a higher-grade interval of 200 meters at 0.58 g/t gold. The analyst described these findings as indicative of "bulk-tonnage targets," with visible gold observed in several drill cores, bolstering the outlook for continued exploration success. [OWNERSHIP_CHART-11131]

Valuation metrics from the report included a projected fair value of CA$0.40 per share, representing a 286% potential upside from the current trading price of CA$0.14. Despite acknowledging the high risks associated with early-stage exploration projects, Couloir Capital emphasized the long-term value potential in a Tier 1 mining jurisdiction, reinforced by the company's experienced management team and promising geological trends.

Ownership and Share Structure

According to Golden Cariboo, management and insiders own 30% of Golden Cariboo Resources. President and CEO Frank Callaghan owns 16.45% or 6.93 million shares; Elaine Callaghan has 0.97% or 0.41 million shares; Director Andrew Rees has 0.79% or 0.33 million shares; and Director Laurence Smoliak has 0.3% or 0.13 million shares.

Retail investors hold the remaining. There are no institutional investors.

The company said it has 50.3 million shares outstanding, 24.83 million warrants, and 3.8 million options.

Its market cap is CA$9.7 million. Over the past 52 weeks, Golden Cariboo has traded between CA$0.08 and CA$0.36 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Golden Cariboo Resources Ltd. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Golden Cariboo Resources Ltd.
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: GCC:CSE; GCCFF:OTC; A0RLEP:WKN;3TZ:FSE, )

Source: Streetwise Reports 11/06/2024

Independence Gold Corp. (IGO:TSX.V; IEGCF:OTCMKTS) has begun a comprehensive diamond drill program at its fully-owned 3Ts Project, located in British Columbia. Positioned 16 km from Artemis Gold Inc.'s Blackwater Project, the 3Ts Project covers 8,840 hectares within a prolific epithermal quartz-carbonate vein district on the Nechako Plateau. The program will consist of approximately 25 drill holes, totaling a minimum of 7,500 meters. The targets are the Ted-Mint and Tommy Vein Systems, with a primary emphasis on unexplored depth zones to identify high-grade intercepts for mineral resource expansion.

The 3Ts Project encompasses multiple identified veins, with strike lengths from 50 to over 1,100 meters and true widths of up to 25 meters. Additional exploration will be directed at the Ian, Johnny, and Larry Veins, focusing on mineralization both along strike and at depth. The Ootsa and Balrog targets, identified through geophysical and geological data collected during the summer 2024 exploration program, are also set to undergo further investigation.

President and CEO Randy Turner stated in the press release, "We look forward to building on the success of recent drill programs at 3Ts. With a larger and more extensive drill program planned, including deeper holes to test the major vein systems below the microdiorite sill and further testing of the newly discovered Ootsa and Balrog targets, we anticipate a very busy and exciting year ahead."

Upon hearing this news, Jeff Clark of The Gold Advisor wrote, "And they're off! This is the THIRD drill program this year at 3Ts, an aggressive schedule that, as investors, we're very happy to see."

He noted that these results will help expand the current resource. He continued, "Remember, management just raised a whopping US$6.65 million, more than double the initial goal, due to strong investor interest. They thus have the financial firepower to conduct all this drilling before winter sets in. The stock isn't reacting to the news, but this isn't something that would normally have a big impact on it. It's cooled from its recent spike so offers a very attractive entry point if you don't have the shares you want. This is an overweight position for me, and it's my belief we'll see more spikes just like the one we witnessed. More news and potential catalysts ahead. This is definitely one to own for the gold bull market."

Looking Into Gold

On October 29, Kitco reported that gold prices approached US$2,800. This reflects a substantial 35% increase for the year. According to the report, this growth resulted from multiple factors, including geopolitical conflicts, Federal Reserve interest rate normalization, strong central bank demand, and political uncertainties surrounding the upcoming presidential election. Analysts described these elements as a "perfect storm," which significantly bolstered investor sentiment and reinforced gold's appeal as a hedge against economic instability.

"This is definitely one to own for the gold bull market," Jeff Clark of The Gold Advisor Wrote.

LiveMint, on October 30, noted the strong performance of precious metals, emphasizing that silver had outpaced gold over the past year. Ankit Gohel from LiveMint mentioned, "Gold has delivered a substantial return of over 33.5% since Dhanteras last year," but highlighted that silver had achieved an even more impressive rally of over 40.5%. Despite this, gold continued to attract attention, with Chintan Mehta, CEO of Abans Holdings, emphasizing gold's role as a safe haven during times of uncertainty. He said, "Gold stands out in times of uncertainty . . . It's a complete safe-haven unlike silver, which always has that industrial component attached to it, adding an extra layer of risk."

In a November 4 article, Egon von Greyerz of Matterhorn Asset Management provided a historical perspective on gold's consistent role in preserving wealth. Von Greyerz discussed how gold had risen 78 times since 1971, when the dollar lost its gold backing, emphasizing that "gold held in the investor's name in safe vaults and jurisdictions outside the financial system is the ultimate form of wealth preservation." He argued that gold's ascent had only just begun, driven by the devaluation of fiat currencies and ongoing global debt expansion.

Independence Catalysts

According to the company's September 2024 investor presentation, the 3Ts Project remains a high-priority asset with substantial growth potential. The updated NI 43-101 compliant resource estimate for the Tommy, Ted, and Mint veins, totaling 522,330 ounces of gold and 13.83 million ounces of silver, is expected to expand with new discoveries and continued drilling. Recent metallurgical testing has returned gold recoveries of up to 97.9%, and the strategic location near Artemis Gold's Blackwater Mine adds further credibility to the project's prospects. [OWNERSHIP_CHART-7643]

The fall 2024 drill program, with a budget of CA$4.5 million, will test high-grade zones and underexplored targets, building on over 63,000 meters of historical drilling. Additionally, new targets such as the Balrog and Ootsa anomalies present significant exploration upside, underscoring the project's potential for resource expansion and discovery.

Ownership and Share Structure

According to Refinitiv, about 4.38% of the company is held by insiders and management.

7.97% is with strategic investor Newmont Corp.

The rest is retail.

Its market cap is CA$29.28 million with 167.8 million shares outstanding. It trades in a 52-week range of CA$0.34 and CA$0.12.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.

2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: IGO:TSX.V;IEGCF:OTCMKTS, )

Source: Streetwise Reports 11/07/2024

Drilling and field operations at Golden Cariboo Resources Ltd.'s (GCC:CSE; GCCFF:OTC; A0RLEP:WKN; 3TZ:FSE) past-producing Quesnelle project in British Columbia's Cariboo Gold District continue to find the yellow metal throughout the project, from visible gold in drill cores to mineralization in outcrop samples.

President and Chief Executive Officer Frank Callaghan told Streetwise Reports that despite the high level of experience on his team, several geologists had never seen visible gold before, and their first views of it were "priceless."

"It was on the outside of this piece of core," Callaghan said. "And then the core had split … and there was more gold on the inside of it, as well."

Callaghan said he's drilled "hundreds and hundreds" of holes, but he "can count on my hands how many times I've seen it (visible gold)."

He said the company is seeing the gold in "every drill hole," so they keep moving forward chasing the deposit and working at the site 24 hours a day.

And according to Callaghan, the structure of the mineralization is "thickening up" as they drill. The technical team has also recognized multiple types of quartz veins that can contain gold, a common feature in large gold deposits of similar nature.

Last month, the company announced it was even forced to stop drilling in a vein zone at the property due to proximity to Osisko Development Corp.'s nearby mineral claims. Drill hole QGQ24-17 was terminated at a depth of 477.32 meters, and the "only thing that stopped us from drilling further was the claim boundary with Osisko," Callaghan said at the time.

On Tuesday, the company announced rock sample results from its 2024 field campaign, which found up to 8.47 grams per tonne gold (g/t Au) in one outcrop in the Halo zone and 1.13 g/t Au in another outcrop near the Pioneer showing.

"Although there is a lot of glacial cover on this project, our geologists still managed to find new gold-bearing outcrops in areas of great significance," Callaghan said in a release announcing the results. "We have now expanded the surface footprint of gold mineralization at the Halo zone to the northeast and increased the strike length of our gold trend. We're in a very large gold system that is being demonstrated by multiple, varied work programs."

Drilling 'Nonstop' and 'Underbudget'

Golden Cariboo, a Canadian explorer-developer, is targeting a potential multimillion-ounce gold resource at the 3,814-hectare Quesnelle project, where gold, silver, lead and zinc were produced historically, according to its Investor Presentation.

The company's neighbors in the mining district include Osisko's Cariboo Gold Project, Spanish Mountain Gold Ltd. (SPA:TSX.V) (Spanish Mountain deposit), Omineca Mining and Metals Ltd. (OMM:TSX.V; OMMSF:OTCMKTS) (Wingdam mine) and Taseko Mines Ltd. (TKO:TSX; TGB:NYSE.MKT) (Gibraltar mine).

Callaghan began rediscovering the Cariboo Camp in the mid-1990s as Barkerville Gold Mines Ltd. He and his then team discovered a gold deposit at Bonanza Ledge and advanced the project to production. He also assembled and developed the Cariboo Gold Project. Ultimately, Osisko Royalties acquired Barkerville and the assets in 2015 for US$338M. Osisko is about to restart mining operations in the camp.

Subsequently, in 2019, Callaghan acquired the Quesnelle Gold Quartz project, where he aims to repeat his previous successes, given the property's geology is similar to that of the other two projects.

Previously, the company reported observing multiple instances of visible gold in several holes earlier this fall and summer.

"Visible gold in current drilling indicates potential for high-grade assays from mineralized targets," Couloir Capital Senior Mining Analyst Ron Wortel wrote in a recent research report.

Given that Golden Cariboo is continuing its exploration program at Quesnelle throughout 2024, near-term catalysts include drill and assay results demonstrating significant grades or widths and better-defined mineralization controls and trends, according to Wortel.

Callaghan told Streetwise Reports that drilling continues to be "nonstop" and underbudget."

External catalysts include market transactions in the junior mining space involving projects or companies in the Cariboo region. Reports by Osisko Development of project advancements or production results relative to adjacent land also could boost Golden Cariboo's stock price.

The Catalyst: Index Also Confirms Bull Run for Junior Stocks

Experts agreed gold is in a bull market and expect it to go higher. However, after hitting a record high of US$2,790.15 per ounce last week, spot gold was down more than 3% to a three-week low on Wednesday morning as investors moved to the U.S. dollar after Donald Trump's election as U.S. president on Tuesday, Reuters reported.

Market participants are also looking ahead to the Federal Reserve's interest rate decision on Thursday for further clues on the bank's easing cycle, Reuters said.

"A clear presidential victory when the market has been pricing in a contested result, removal of an element of risk, Trump-trades include the dollar's strengthening this morning and the combination of the two has brought gold lower," StoneX analyst Rhona O'Connell said, according to Reuters.

Gold's rise has "resulted in big returns for the investors who bought in earlier this year," Angelica Leicht reported for CBS News last month. "For example, the investors who purchased gold in March when it hit US$2,160 per ounce have seen their gold values increase by nearly 27% in the time since. That's a huge uptick in value in a matter of months, especially on an asset that's known more for long-term growth."

Recently polled London Bullion Market Association members indicated they believe the gold price could reach US$2,940/oz during 2025, reported Stockhead on Oct. 28.[OWNERSHIP_CHART-11131]

"Combined with expectations of lower global interest rates, this further enhances gold's attractiveness as an investment," the article noted.

As for gold equities, the S&P/TSX Venture Composite Index (SPCDNX) confirmed a bull run for junior, intermediate, and senior mining stocks when it closed above 1,000 recently, Stewart Thomson with 321Gold wrote. The index is a key indicator of the health of the general gold, silver, and mining stocks market.

Ownership and Share Structure

According to Golden Cariboo, management and insiders own 30% of Golden Cariboo Resources. President and CEO Frank Callaghan owns 16.45% or 6.93 million shares; Elaine Callaghan has 0.97% or 0.41 million shares; Director Andrew Rees has 0.79% or 0.33 million shares; and Director Laurence Smoliak has 0.3% or 0.13 million shares.

Retail investors hold the remaining. There are no institutional investors.

The company said it has 50.3 million shares outstanding, 24.83 million warrants, and 3.8 million options.

Its market cap is CA$9.63 million. Over the past 52 weeks, Golden Cariboo has traded between CA$0.08 and CA$0.36 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Omineca Mining and Metals Ltd. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000.
2. Golden Cariboo Resources Ltd. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
3. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Golden Cariboo Resources Ltd. and Omineca Mining and Metals Ltd.
4. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
5. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

For additional disclosures, please click here.

( Companies Mentioned: GCC:CSE; GCCFF:OTC; A0RLEP:WKN;3TZ:FSE, )

Gay and bisexual men in England, Scotland, and Wales can now donate blood, plasma and platelets under certain circumstances without having to wait three months, the National Health Service announced this week.; Credit: Wilfredo Lee/AP

Gay and bisexual men in England, Scotland, and Wales can now donate blood, plasma and platelets under certain circumstances, the National Health Service announced this week in a momentous shift in policy for most of the U.K.

Beginning Monday, gay men in sexually active, monogamous relationships for at least three months can donate for the first time. The move reverses a policy that limited donor eligibility on perceived risks of contracting HIV/AIDs and other sexually transmitted infections.

The new rules come as the U.K. and other countries around the world report urgent, pandemic-induced blood supply issues.

Donor eligibility will now be based on each person's individual circumstances surrounding health, travel and sexual behaviors regardless of gender, according to the NHS. Potential donors will no longer be asked if they are a man who has had sex with another man, but they will be asked about recent sexual activity.

Anyone who has had the same sexual partner for the last three months can donate, the NHS said.

"Patient safety is at the heart of everything we do. This change is about switching around how we assess the risk of exposure to a sexual infection, so it is more tailored to the individual," said Ella Poppitt, Chief Nurse for blood donation at NHS Blood and Transplant, in a statement. "We screen all donations for evidence of significant infections, which goes hand-in-hand with donor selection to maintain the safety of blood sent to hospitals."

People who engage in anal sex with a new partner or multiple people or who have recently used PrEP or PEP (medication used to prevent HIV infection) will have to wait three months to donate - regardless of their gender.

Why did the U.K. make this change?

The NHS moved to alter its blood donation eligibility rules following a review by the FAIR (For the Assessment of Individualised Risk) steering group. The panel determined an individualized, gender-neutral approach to determining who can donate blood, platelets, and plasma is fairer and still maintains the safety of the U.K.'s blood supply.

The findings were accepted in full by the government last December.

Researchers will continue to monitor the impact of the donor selection changes for the next 12 months to determine if more changes are needed, NHS said.

What is the policy in the U.S.?

Despite efforts by advocates to change regulations in the U.S, the ability for gay and bisexual men to donate blood is still restricted.

A ban on gay and bisexual blood donors has been in effect since the early 1980s when fears about HIV/AIDS were widespread.

The Food and Drug Administration's current policy states a man who has sex with another man in the previous three months can't donate. Federal rules previously made such donors wait 12 months before giving blood, but due to low blood supplies during the pandemic the federal government changed the policy in April.

The Red Cross said they are participating in a pilot study funded by the FDA using behavior-based health history questionnaires, similar to those used in the U.K.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: /Joy Ho for NPR

Perhaps the only respite pandemic closures brought to my family — which includes two kids under age 6 — was freedom from the constant misery of dripping noses, sneezes and coughs. And statistics suggest we weren't the only ones who had fewer colds last year: With daycares and in-person schools closed and widespread use of masks and hand sanitizer in most communities, cases of many seasonal respiratory infections went down, and flu cases dropped off a cliff.

That reprieve might be ending. Social mixing has been starting up again in much of the U.S. and so have cases of garden-variety sniffles. The Centers for Disease Control and Prevention just warned physicians that RSV, a unpleasant respiratory virus, is surging right now in southern states. And it's not just happening in the U.S. — researchers in the U.K. and Hong Kong found that rhinovirus outbreaks spiked there, too, when COVID-19 lockdowns ended.

My family is at the vanguard of this trend. Right after Washington D.C. lifted its mask mandate a few weeks ago, both my kids got runny noses and coughs, and as soon as they tested negative for COVID-19, my pandemic fears were replaced by a familiar dread. I had visions of sleepless, cough-filled nights, dirty tissues everywhere, and — in short order — my own miserable cold.

"If someone in your house is sick, you're not only breathing in their sick air, you're touching those contaminated surfaces. You're having closer contact, you're having longer exposures," says Seema Lakdawala, a researcher at the University of Pittsburgh School of Medicine, who studies how influenza viruses transmit between people. It can start to feel inevitable that the whole family will get sick.

Take heart, my fellow parents-of-adorable-little-germ-machines! Lakdawala says many strategies we all picked up to fight COVID-19 can also stop the spread of many routine respiratory viruses. In fact, they may be even more effective against run-of-the-mill germs, since, unlike the viruses behind most colds, SARS-CoV2 was new to the human immune system.

Those strategies start with everyone keeping their children home from school, camp and playdates when they're sick and keeping up with any and all vaccinations against childhood illnesses. Beyond that, specialists in infectious disease transmission I consulted offer five more tips for keeping my family and yours healthier this summer.

Tip #1: Hang on to those masks

In pre-pandemic times, it might have seemed like a weird move to put on a mask during storytime with your drippy-nosed kid, but Dr. Tina Tan says that's her top tip. She's a professor of pediatrics at the Feinberg School of Medicine at Northwestern University and a pediatric infectious disease physician at Lurie Children's Hospital in Chicago.

When it comes to influenza, a rhinovirus, or any of the other respiratory bugs constantly circulating, "once these viruses touch your mucous membranes, whether it's your eyes, your nose or your mouth, you do have a chance of contracting it," says Tan. Masks help stop infectious particles and virus-filled droplets from getting into your body.

"You don't need a N95," Tan says. A light-weight surgical mask or homemade cloth mask can work as long as it has two or more layers. The mask-wearing also doesn't have to be constant. "If you're going to be face to face with them — they're sitting in your lap, you're reading to them, you're feeding them, etc. — then I would say wear a mask," Tan advises.

Even better, if it's not too uncomfortable for your sick child, have them wear a mask, Lakdawala says. "If your kids are old enough to wear a mask, that would probably be the best strategy, because then you're reducing the amount of virus-laden aerosols in the environment."

How long should you stay masked-up?

For most respiratory viruses, "the infectious period is probably similar to that of COVID," says Dr. Jennifer Shu, a pediatrician in Atlanta and medical editor of the American Academy of Pediatrics' site HealthyChildren.org. It might technically start a few days before symptoms begin and last for up to two weeks, but your sniffly kids are likely most contagious during those first runny-nosed days Shu says. "You could have kids over [age] 2 wear a mask for the first three or four days of symptoms," she suggests.

And if you can't bring yourself to wear a mask or put one on your child inside your own home to fight a cold, don't worry. Lakdawala has a few more ideas.

Tip #2: Air it out, space it out

When Lakdawala's 5- and 8-year-old kids get sick, "I open the windows, I turn on the fans, I get a lot more air circulation going on in the house," she says — that is, weather and allergies permitting, of course.

"A lot of these viruses tend to circulate more during the colder weather, so where you live is going to determine how much you can open your windows," Tan points out. But certainly, she says, "the better the ventilation, the less likely the viruses are going to get transmitted from one person to another."

What about buying HEPA filter air purifiers, or changing the filter in your heating and air conditioning system? "I would not suggest going out to purchase extra HEPA filters just for this purpose," says Dr. Ibukun Kalu, a pediatric infectious disease physician at Duke University. For hospitals that are treating very contagious and serious pathogens like tuberculosis or SARS-CoV2, those upgrades may be important, she says. "But for all of the other routine viruses, it's routine ventilation."

Kalu says you might also want to think strategically about creating some social distance — when it's possible — like strategically having the parent who tends not to get as sick provide the one-on-one care for the sick kid.

Obviously, you can't isolate a sick child in a room by themselves until they recover, but Lakdawala says not getting too close or for too long can help. When her kids are sick, "I do try to just not snuggle them — keep them a little bit at a distance."

Tip #3: Don't try to be a HAZMAT team

There's good news on the house-cleaning front. "Most of these viruses don't live on surfaces for very long periods of time," says Tan.

The research on exactly how long cold-causing rhinoviruses can survive on surfaces — and how likely they are to remain infectious — isn't definitive. As Dr. Donald Goldmann of Boston Children's Hospital poetically put it in The Pediatric Infectious Disease Journal a couple decades ago, "Despite many years of study, from the plains of Salisbury, to the hills of Virginia, to the collegiate environment of Madison, WI, the precise routes rhinovirus takes to inflict the misery of the common cold on a susceptible population remain controversial." That's still true today, doctors say.

There's some evidence that contaminated surfaces are not very important in the spread of colds. In one little study from the 1980s, a dozen healthy men played poker with cards and chips that "were literally gummy" from the secretions of eight other men who had been infected with a rhinovirus as part of the study. Even after 12 hours of poker, none of the healthy volunteers caught colds.

Shu's take home advice? Be methodical in your cleaning of often-touched surfaces (kitchen table, countertops and the like) with soap and water when everybody's healthy, and maybe add bleach wipes or other disinfectant when someone in your household has a cold. But don't panic.

Tan agrees. "Wipe down frequently-touched surfaces multiple times a day," she says. "But you don't have to go crazy and, like, scour everything down with bleach."

You also don't need to do a lot of extra laundry in hopes of eliminating germs on clothes, towels, dishtowels and the like — that can be exhausting and futile. Instead, just try to encourage kids who are sick to use their own towel — and do what you can to give towels a chance to dry out between uses. "Having some common sense and doing laundry every few days — washing your towels every few days and washing your sheets every couple of weeks — is probably good enough," Shu says. "You don't need to go overboard for run-of-the-mill viruses."

Don't fret that there are germs everywhere and you can't touch anything, says Lakdawala. "If I touch something, that -- in itself — is not infecting me," she notes. Instead, it's getting a certain amount of virus on our hands and then touching our own nose, eyes or mouth that can infect us. "If I just go wash my hands, that risk is gone," Lakdawala says.

You can also skip wearing gloves around the house. "People think that they are safe when they're wearing the gloves — and then they touch their face with their gloves [on]" and infect themselves, she says.

Instead, just make it a habit to wash your hands frequently.

Tip #4: Seriously, just wash your hands

"The same handwashing guidelines for COVID also apply for common respiratory illnesses," Shu says. That is: regular soap with warm water, lathered for about 20 seconds.

"The reason why 20 seconds is recommended is because some studies show that washing your hands shorter than that doesn't really get rid of germs." She warns that there hasn't been a whole lot of research on this, and 20 seconds is not a magic number. "But it is thought that anywhere from 15 to 30 seconds is probably good enough to get rid of most of the germs," she says. (Note: No need to drive your family crazy singing the birthday song twice — y'all have options.)

"Wash your hands before you eat, after you eat, after you go to the bathroom ... if you're changing your child's diaper, et cetera.," says Tan. "And if you're going to use hand sanitizer, it has to be at least 60% alcohol."

"Your hands are probably the most important source of transmission outside of someone really coughing or sneezing in your face," Kalu adds.

Tip #5: Don't give up, but do keep perspective

So, what if your beloved child does cough or sneeze in your face? Should you then forget all this stuff and just give in to the inevitable?

Don't give up, says Lakdawala. "Just because you got one large exposure in your mouth and in close range, it doesn't mean that that was sufficient to initiate an infection," she says. Whether you get sick from that germy onslaught is going to depend on a lot of things — the particular virus, whether the sneeze landed in your mouth or nose, whether you've been exposed to some version of that virus before and more.

One tiny positive side effect of the coronavirus pandemic for Lakdawala has been a broader public understanding of "dose-response" in viral transmission. "Just because somebody breathed on you once doesn't necessarily mean that that's what's going to get you infected," she says.

Consider practicing the swiss cheese model of transmission control, Shu says. "Every layer of protection helps — if you find that wearing a face shield is too much, but you do everything else, you're still going to limit your exposure," she says. Just do what works for you and your family.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A teen gets a dose of Pfizer's COVID-19 vaccine at Holtz Children's Hospital in Miami on May 18. Nearly 7 million U.S. teens and pre-teens (ages 12 through 17) have received at least one dose of a COVID-19 vaccine, so far, the CDC says.; Credit: Eva Marie Uzcategui/Bloomberg via Getty Images

It's been a little more than a month since adolescents as young as 12 became eligible in the United States to receive the Pfizer vaccine against COVID-19, and nearly all reports have been positive: The vaccine is very effective in this age group, and the vast majority of kids experience mild side effects, if any — the same sore arm or mild flu-like symptoms seen among adults who get the shot.

The Centers for Disease Control and Prevention has recommended that everyone 12-years-old and older get vaccinated against COVID-19, and the rollout is well underway: According to the CDC, nearly 7 million U.S. teens and pre-teens (ages 12 through 17) have received at least one dose of a COVID-19 vaccine, so far.

Still, soon after the FDA authorized the use of Pfizer's vaccine in young people, federal agencies began receiving reports of mild chest pain or other signs of possible heart inflammation (known as myocarditis) in a very small percentage of recently vaccinated teens.

CDC director Rochelle Walensky said at a White House briefing Friday that there have been more than 300 cases of heart inflammation reported among more than 20 million teens and young adults who have received one of the vaccines made by Moderna or Pfizer. She said that in the "vast majority" of cases, the inflammation went away.

An expert advisory committee to the health agency is expected to review the cases in more depth at a meeting Friday.

So, in the meantime, should parents of teens hesitate to have their kids vaccinated against COVID-19? Vaccine experts and the American Academy of Pediatrics say no, don't hesitate. It's good for doctors and patients to be aware that there might be a connection between the mRNA vaccines and heart inflammation, and to report to their pediatrician anything they see in that first week after vaccination. But it is also important, the CDC notes, to recognize that even if this does turn out to be an extremely rare side effect of the vaccine, "most patients who received care responded well to medicine and rest and quickly felt better." And the serious risks of COVID -19 — even for young healthy people — outweigh the risks of any possible side effects from the vaccine. Here are some questions you may have, and what's known:

What exactly is myocarditis?

Myocarditis is an inflammation of the heart muscle, and pericarditis, also being investigated, is an inflammation of the sac around the heart.

Long before the pandemic, thousands of cases of myocarditis were diagnosed in the U.S. and around the world each year, often triggered by the body's immune response to infections. SARS-CoV-2 can trigger it, and so can cold viruses, and staph and strep and HIV. Other causes include toxins and allergies.

Symptoms include chest pain and shortness of breath. It's often mild enough to go unnoticed, but a full-blown case in adults can cause arrhythmias and heart failure that require careful treatment with multiple medications, and several months of strict rest. In a case study of seven teenagers who got myocarditis following vaccination published last week in the journal Pediatrics, all seven got better after routine treatment with anti-inflammatory drugs.

Pediatric cardiologist Dr. Stuart Berger of the Northwestern University Feinberg School of Medicine, a spokesperson for the American Academy of Pediatrics, says vaccine-related myocarditis in teens is not all that worrisome. "Although they appear with some symptoms of chest pain, and maybe some findings on EKGs, all of the cases we've seen have been on the mild end of the spectrum," he says.

So, what's the concern?

Several hundred reports about the inflammation have been filed with the federal government's Vaccine Adverse Event Reporting System (VAERS); that's a repository of reports sent in by health professionals and patients about any health events they spot in the hours or days after vaccinations. Many of the events reported turn out to be coincidental — not caused by a vaccine. The database is just meant as a starting point for further investigation and not proof of cause and effect. But as NPR's Geoff Brumfiel noted this week, "when millions of people are vaccinated within a short period, the total number of these reported events can look big."

That said, anecdotes reported by doctors in medical journals and reports to VAERS suggest that both of the mRNA vaccines authorized for use in the U.S. — the Pfizer and Moderna vaccines — might slightly increase the incidence of myocarditis in young people. In 2003, a report in the New England Journal of Medicine estimated the background incidence of myocarditis to be 1.13 cases in 100,000 children per year.

Paul Offit, professor of pediatrics at the Children's Hospital of Philadelphia and a member of a Food and Drug Administration vaccine advisory committee says there likely is a causal link between the heart inflammation some doctors are seeing in these teens and the second dose of vaccine. "I think it's real," he says, but hastens to add that the effect is exceedingly small – based on the data collected so far, maybe one in 50,000 vaccinees between the ages of 16 and 39. "And the good news is at least so far it looks to be transient and self-resolving."

Still, maybe I should wait to get my teen vaccinated and see how this plays out?

Uhm, no, according to several vaccine experts contacted by NPR. And this is where a little math comes in handy.

"Take a stadium full of 100,000 people between the ages of 16 and 39, which is the subset that appears to be at greater risk," Offit says. "Vaccinate all of them, and two might get myocarditis." But if you don't vaccinate any of the 100,000, he estimates that about 1,300 would eventually get COVID-19. And those numbers are likely to increase this winter.

About one in 1,000 children who get COVID-19 have gone on to develop a condition called MIS-C (multisystem inflammatory syndrome in children), says Offit, and most of those kids have had some level of myocarditis. In addition, the new coronavirus has directly caused myocarditis in some children and adults. Which of the two stadiums in Offit's metaphor would have more cases of myocarditis — the vaccinated children or unvaccinated kids — is not known precisely. But Offit says he suspects it would be the unvaccinated group. And there's no doubt that 1,000 unvaccinated children would suffer more COVID-19-related illnesses. "A choice not to get a vaccine is not a choice to avoid myocarditis," he says. "It's a choice to take a different risk — and I would argue a more serious one" — of developing a bad case of COVID-19 or long-COVID or COVID-caused myocarditis.

Are the experts advising their own kids in this age group to get vaccinated?

Yes. "I understand people having concerns," says Dr. Judith Guzman-Cottrill. She's a parent and professor of pediatric infectious diseases at the Oregon Health and Science University, as well as the senior author on a small study that came out this month in the journal Pediatrics. In the report, Guzman-Cottrill and her colleagues analyzed the cases of seven boys around the country who developed myocarditis within four days of receiving the Pfizer-BioNTech vaccine.

She and her family recently faced the vaccination decision for her own 13-year-old daughter — and said a whole-hearted yes to the shot.

Guzman-Cottrill suspects there may turn out to be a slightly increased risk of heart inflammation from vaccination in young people, but she and her co-authors note in the Pediatrics report that a direct cause-and-effect connection — even in these seven cases — has yet to be established. And she's impressed that despite the millions of doses that have so far been delivered to teens, no clear and serious post-vaccination problems have shown up. "The emergency departments and urgent care clinics are not filled with teenagers complaining of chest pain," she says.

She's treated unvaccinated teens who developed severe myocarditis from an infection with the COVID-19 virus, and others who developed COVID-19 pneumonia and respiratory failure. Seeing those teens struggle — teens who lacked the powerful immune protection the vaccine provides — was enough for her to suggest vaccination to her daughter, who got her second vaccination earlier this week.

"She saw it as a pathway back to a normal post pandemic life," Guzman-Cottrill says.

And that's where public health comes in. "We really need a highly vaccinated student body when kids return to the classroom this fall," says Guzman-Cottrill, "so we don't see surges in COVID-19 cases."

Joanne Silberner, a former health policy correspondent for NPR, is a freelance journalist living in Seattle.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The pandemic has taken a massive toll on people's mental health. But a new report by the U.S. Centers for Disease Control and Prevention confirms what many of us are seeing and feeling in our own lives: The impact has been particularly devastating for parents and unpaid caregivers of adults.

Two-thirds of survey respondents who identified as unpaid caregivers said they experienced mental health challenges during the pandemic, such as symptoms of anxiety or depression, or suicidal thoughts.

Only one-third of people with no caregiving responsibilities reported the same symptoms.

Of the more than 10,000 survey respondents, more than 40% identified as being unpaid caregivers.

"What is striking here is just how widespread unpaid caregiving responsibilities are in the population and how much of a burden and a toll these responsibilities" are having, says Shantha Rajaratnam, a co-author of the study and a psychologist at the Turner Institute of Brain and Mental Health at Monash University in Australia.

The study also found that people who care for both children under 18 and adults — many of them part of the sandwich generation — are faring the worst, with 85% of this group experiencing adverse mental health symptoms.

"It's an extremely important study," says psychologist Dolores Gallagher-Thompson, professor emeritus at Stanford University who has researched family caregivers and their challenges.

The study is the first to document the problems caregivers have experienced during COVID-19, she notes, and underscores "the importance of paying attention to caregiver issues, caregiver mental health" and the need for education and resources to better support them.

The contrast between caregivers and others is stark

The study, part of ongoing research by The COVID-19 Outbreak Public Evaluation (COPE) Initiative, is based on surveys conducted in December 2020 and February-March 2021.

More than half of those who identified as caregivers said they had experienced symptoms of anxiety or depression, or of disorders like PTSD related to the stress and trauma of COVID-19.

A significant number of caregivers said they had contemplated suicide. Nearly 40% reported having passive suicidal thoughts, meaning "wishing that they had gone to bed and didn't wake up," says study co-author Mark Czeisler, a graduate student at Monash University and a research trainee at Brigham and Women's Hospital in Boston.

And more than 30% had seriously considered taking their own life — about five times the number of noncaregivers, the study found.

Across the board, mental health impacts have been more severe for people who care for both children and adults. Half of this group said it had seriously considered suicide in the past month.

The pandemic worsened the challenges caregivers face

Even before the pandemic, being an unpaid caregiver was stressful and associated with a higher risk of mental health issues, says Gallagher-Thompson. The COVID-19 pandemic has made things even harder.

For instance, the pandemic has taken away many formal and informal sources of support for caregivers.

That was the case for Dr. Nicole Christian-Brathwaite. She's a Boston-based child psychiatrist and lives with her husband, her mother, her husband's father and two sons, who are 4 and 6.

Before the pandemic, her father-in-law, who has dementia, went to a day program for seniors with cognitive decline. Her mother, a survivor of breast and lung cancers, went to physical therapy twice a week, doctor appointments and met with friends.

When the pandemic hit, they lost those services and social support — at the same time Christian-Brathwaite and her husband began working from home while taking care of their sons and parents.

Life at home became much more complicated. Her sons developed behavioral problems with the transitions and stresses of the pandemic. Her mother struggled with chronic pain, and was hospitalized during the pandemic. And there were days when her father-in-law was confused, disoriented or aggressive.

"Many days I was walking around on edge waiting for something to happen because our entire setup was so very fragile and vulnerable," says Christian-Brathwaite. "It's been exhausting."

And her mental health has suffered. "I certainly was dealing with insomnia," she says. "I was short tempered. I was more irritable. I didn't have the same tolerance for things."

More support needed to help caregivers cope

The new study highlights the extent to which unpaid caregivers have struggled during the pandemic, says Gallagher-Thompson.

"There are some serious issues here that shouldn't be ignored," she says.

And yet caregivers are often ignored by the health system, which is set up to focus only on patients.

"Family members are rarely asked, 'How does this affect you? What is difficult? How can we help you? How can we support you in being able to carry out your role, your tasks, your responsibilities?'" Gallagher-Thompson says.

As the new study shows, support can make a big difference — respondents who could rely on others for help with caregiving had a lower incidence of mental health symptoms.

So it's important to educate and support caregivers. For example, physicians can start by screening their patients' caregivers for mental health symptoms and provide more resources to those who need it, says Gallagher-Thompson.

Christian-Brathwaite hopes the new study will help physicians recognize that family caregivers are just as important to consider while treating patients.

"We really need to take a step back and look at the village that's around them because our patients can't be successful without having the support from family," she says.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The dangerous Delta variant of the coronavirus is spreading so quickly in the United States that it's likely the mutant strain will become predominant in the U.S. within weeks, according to a new analysis.

The variant, first identified in India, is the most contagious yet and, among those not yet vaccinated, may trigger serious illness in more people than other variants do, say scientists tracking the spread of infection.

The Delta variant apparently already accounts for at least 14% of all new infections, according to the research analysis posted online Monday of more than 242,000 infections nationwide over the last six months.

Another reason to get vaccinated

"It definitely is of concern," says William Lee, the vice president of science at Helix, which is under contract with the Centers for Disease Control and Prevention to help track the variants.

"Just the fact that it's so transmissible means that it's it's dangerous," Lee says, "and so I think you'll see outbreaks of Delta around the country and more people will get sick from it."

Helix launched the study when researchers spotted a drop in the prevalence of the Alpha variant, a contagious strain first spotted in the U.K. that had quickly become the dominant variant in that country and the U.S.

The researchers discovered the drop in relative frequency of the Alpha variant in their spot checks of strains circulating in the U.S. was due to a rapid increase in two other variants: the Gamma variant, first spotted in Brazil, and the Delta variant. The Gamma variant may be slightly better than the original strain at outmaneuvering the vaccines, researchers say.

"It looks like both of them are going to slowly push out Alpha," says Lee, whose study has not yet been peer-reviewed but has been posted on a pre-print server.

How Delta could prompt another U.S. COVID-19 surge

All the vaccines authorized for use in the U.S. appear, in general, to provide powerful protection against all the variants, including Delta. But the rapid spread of the variants is still raising concern because of the large number of people who remain unvaccinated.

"There still are big portions of the country where the rates of vaccination are quite low," notes Dr. Jeremy Luban, a virologist at the University of Massachusetts Medical School. "And, in fact, the Helix paper shows that this Delta variant is increasing in frequency — the speed at which it's increasing in frequency is greatest in those areas where vaccination rates are lowest."

The Delta variant could trigger yet another moderate surge of infections through many parts of the U.S. because of these pockets of unvaccinated people, according to a recent set of projections from the COVID-19 Scenario Modeling Hub, which is helping the CDC plot the future course of the pandemic.

The projections indicate that infections could start to rise again as soon as some time in July, especially if the vaccination campaign continues to stall.

"For the most part, it's a moderate resurgence," says Justin Lessler, an epidemiologist at Johns Hopkins University who is helping coordinate the hub.

"We're not having massive epidemics at a national level, but we have this kind of continuation of the virus just sticking around and keeping us on our toes," Lessler says. "And in specific places there could be substantial epidemics still."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, leads some of the Biden administration's efforts to expand Medicaid access.; Credit: Caroline Brehman/CQ-Roll Call, Inc via Getty Imag

The Biden administration is quietly engineering a series of expansions to Medicaid that may bolster protections for millions of low-income Americans and bring more people into the program.

Biden's efforts — which have been largely overshadowed by other economic and health initiatives — represent an abrupt reversal of the Trump administration's moves to scale back the safety-net program.

The changes could further boost Medicaid enrollment — which the pandemic has already pushed to a record 80.5 million. Some of the expansion is funded by the COVID-19 relief bill that passed in March, including coverage for new mothers.

Others who could also gain coverage under Biden are inmates and undocumented immigrants. At the same time, the administration is opening the door to new Medicaid-funded services such as food and housing that the government insurance plan hasn't traditionally offered.

"There is a paradigm change underway," said Jennifer Langer Jacobs, Medicaid director in New Jersey, one of a growing number of states trying to expand home-based Medicaid services to keep enrollees out of nursing homes and other institutions.

"We've had discussions at the federal level in the last 90 days that are completely different from where we've ever been before," Langer Jacobs said.

Taken together, the Medicaid moves represent some of the most substantive shifts in federal health policy undertaken by the new administration.

"They are taking very bold action," said Rutgers University political scientist Frank Thompson, an expert on Medicaid history, noting in particular the administration's swift reversal of Trump policies. "There really isn't a precedent."

The Biden administration seems unlikely to achieve what remains the holy grail for Medicaid advocates: getting 12 holdout states, including Texas and Florida, to expand Medicaid coverage to low-income working-age adults through the Affordable Care Act.

And while some of the recent expansions – including for new mothers -- were funded by close to $20 billion in new Medicaid funding in the COVID relief bill Biden signed in March, much of that new money will stop in a few years unless Congress appropriates additional money.

The White House strategy has risks. Medicaid, which swelled after enactment of the 2010 health law, has expanded further during the economic downturn caused by the pandemic, pushing enrollment to a record 80.5 million, including those served by the related Children's Health Insurance Program. That's up from 70 million before the COVID crisis began.

The programs now cost taxpayers more than $600 billion a year. And although the federal government will cover most of the cost of the Biden-backed expansions, surging Medicaid spending is a growing burden on state budgets.

The costs of expansion are a frequent target of conservative critics, including Trump officials like Seema Verma, the former administrator of the Centers for Medicare & Medicaid Services, who frequently argued for enrollment restrictions and derided Medicaid as low-quality coverage.

But even less partisan experts warn that Medicaid, which was created to provide medical care to low-income Americans, can't make up for all the inadequacies in government housing, food and education programs.

"Focusing on the social drivers of health ... is critically important in improving the health and well-being of Medicaid beneficiaries. But that doesn't mean that Medicaid can or should be responsible for paying for all of those services," said Matt Salo, head of the National Association of Medicaid Directors, noting that the program's financing "is simply not capable of sustaining those investments."

Restoring federal support

However, after four years of Trump administration efforts to scale back coverage, Biden and his appointees appear intent on not only restoring federal support for Medicaid, but also boosting the program's reach.

"I think what we learned during the repeal-and-replace debate is just how much people in this country care about the Medicaid program and how it's a lifeline to millions," Biden's new Medicare and Medicaid administrator, Chiquita Brooks-LaSure, told KHN, calling the program a "backbone to our country."

The Biden administration has already withdrawn permission the Trump administration had granted Arkansas and New Hampshire to place work requirements on some Medicaid enrollees.

In April, Biden blocked a multibillion-dollar Trump administration initiative to prop up Texas hospitals that care for uninsured patients, a policy that many critics said effectively discouraged Texas from expanding Medicaid coverage through the Affordable Care Act, often called Obamacare. Texas has the highest uninsured rate in the nation.

The moves have drawn criticism from Republicans, some of whom accuse the new administration of trampling states' rights to run their Medicaid programs as they choose.

"Biden is reasserting a larger federal role and not deferring to states," said Josh Archambault, a senior fellow at the conservative Foundation for Government Accountability.

But Biden's early initiatives have been widely hailed by patient advocates, public health experts and state officials in many blue states.

"It's a breath of fresh air," said Kim Bimestefer, head of Colorado's Department of Health Care Policy and Financing.

Chuck Ingoglia, head of the National Council for Mental Wellbeing, said: "To be in an environment where people are talking about expanding health care access has made an enormous difference."

Mounting evidence shows that expanded Medicaid coverage improves enrollees' health, as surveys and mortality data in recent years have identified greater health improvements in states that expanded Medicaid through the 2010 health law versus states that did not.

Broadening eligibility

In addition to removing Medicaid restrictions imposed by Trump administration officials, the Biden administration has backed a series of expansions to broaden eligibility and add services enrollees can receive.

Biden supported a provision in the COVID relief bill that gives states the option to extend Medicaid to new mothers for up to a year after they give birth. Many experts say such coverage could help reduce the U.S. maternal mortality rate, which is far higher than rates in other wealthy nations.

Several states, including Illinois and New Jersey, had sought permission from the Trump administration for such expanded coverage, but their requests languished.

The COVID relief bill — which passed without Republican support — also provides additional Medicaid money to states to set up mobile crisis services for people facing mental health or substance use emergencies, further broadening Medicaid's reach.

And states will get billions more to expand so-called home and community-based services such as help with cooking, bathing and other basic activities that can prevent Medicaid enrollees from having to be admitted to expensive nursing homes or other institutions.

Perhaps the most far-reaching Medicaid expansions being considered by the Biden administration would push the government health plan into covering services not traditionally considered health care, such as housing.

This reflects an emerging consensus among health policy experts that investments in some non-medical services can ultimately save Medicaid money by keeping patients out of the hospital.

In recent years, Medicaid officials in red and blue states — including Arizona, California, Illinois, Maryland and Washington — have begun exploring ways to provide rental assistance to select Medicaid enrollees to prevent medical complications linked to homelessness.

The Trump administration took steps to support similar efforts, clearing Medicare Advantage health plans to offer some enrollees non-medical benefits such as food, housing aid and assistance with utilities.

But state officials across the country said the new administration has signaled more support for both expanding current home-based services and adding new ones.

That has made a big difference, said Kate McEvoy, who directs Connecticut's Medicaid program. "There was a lot of discussion in the Trump administration," she said, "but not the capital to do it."

Other states are looking to the new administration to back efforts to expand Medicaid to inmates with mental health conditions and drug addiction so they can connect more easily to treatment once released.

Kentucky health secretary Eric Friedlander said he is hopeful federal officials will sign off on his state's initiative.

Still other states, such as California, say they are getting a more receptive audience in Washington for proposals to expand coverage to immigrants who are in the country without authorization, a step public health experts say can help improve community health and slow the spread of communicable diseases.

"Covering all Californians is critical to our mission," said Jacey Cooper, director of California's Medicaid program, known as Medi-Cal. "We really feel like the new administration is helping us ensure that everyone has access."

The Trump administration moved to restrict even authorized immigrants' access to the health care safety net, including the "public charge" rule that allowed immigration authorities to deny green cards to applicants if they used public programs such as Medicaid. In March, Biden abandoned that rule.

KHN correspondent Julie Rovner contributed to this report.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation). KFF is an endowed nonprofit organization providing information on health issues to the nation.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A COVID-19 vaccination clinic last month in Auburn, Maine. A drop in life expectancy in the U.S. stems largely from the coronavirus pandemic, a new study says.; Credit: Robert F. Bukaty/AP

A new study estimates that life expectancy in the U.S. decreased by nearly two years between 2018 and 2020, largely due to the COVID-19 pandemic. And the declines were most pronounced among minority groups, including Black and Hispanic people.

In 2018, average life expectancy in the U.S. was about 79 years (78.7). It declined to about 77 years (76.9) by the end of 2020, according to a new study published in the British Medical Journal.

"We have not seen a decrease like this since World War II. It's a horrific decrease in life expectancy," said Steven Woolf of the Virginia Commonwealth University School of Medicine and an author of the study released on Wednesday. (The study is based on data from the National Center for Health Statistics and includes simulated estimates for 2020.)

Beyond the more than 600,000 deaths in the U.S. directly from the coronavirus, other factors play into the decreased longevity, including "disruptions in health care, disruptions in chronic disease management, and behavioral health crisis, where people struggling with addiction disorders or depression might not have gotten the help that they needed," Woolf said.

The lack of access to care and other pandemic-related disruptions hit some Americans much harder than others. And it's been well documented that the death rate for Black Americans was twice as high compared with white Americans.

The disparity is reflected in the new longevity estimates. "African Americans saw their life expectancy decrease by 3.3 years and Hispanic Americans saw their life expectancy decrease by 3.9 years," Woolf noted.

"These are massive numbers," Woolf said, that reflect the systemic inequalities that long predate the pandemic.

"It is impossible to look at these findings and not see a reflection of the systemic racism in the U.S.," Lesley Curtis, chair of the Department of Population Health Sciences at Duke University School of Medicine, told NPR.

"This study further destroys the myth that the United States is the healthiest place in the world to live," Dr. Richard Besser, president of the Robert Wood Johnson Foundation (an NPR funder), said in an email.

He said wide differences in life expectancy rates were evident before COVID-19. "For example, life expectancy in Princeton, NJ—a predominantly White community—is 14 years higher than Trenton, NJ, a predominantly Black and Latino city only 14 miles away," Besser said.

Life expectancy in the U.S. had already been declining — albeit slowly — in the years leading up to the pandemic. And the U.S. has been losing ground compared with other wealthy countries, said Magali Barbieri of the University of California, Berkeley, in an editorial published alongside the new study.

The study estimates that the decline in life expectancy was .22 years (or about one-fifth of a year) in a group of 16 peer countries (including Austria, Finland, France, Israel, the Netherlands and the United Kingdom) compared with the nearly two-year decline in the United States.

"The U.S. disadvantage in mortality compared with other high income democracies in 2020 is neither new nor sudden," Barbieri wrote. It appears the pandemic has magnified existing vulnerabilities in U.S. society, she added.

"The range of factors that play into this include income inequality, the social safety net, as well as racial inequality and access to health care," Duke's Curtis said.

So, what's the prognosis going forward in the United States? "I think life expectancy will rebound," Woolf of Virginia Commonwealth said.

But it's unlikely that the U.S. is on course to reverse the trend entirely.

"The U.S. has some of the best hospitals and some of the greatest scientists. But other countries do far better in getting quality medical care to their population," Woolf said. "We have big gaps in getting care to people who need it most, when they need it most."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Housing activists erect a sign in front of Massachusetts Gov. Charlie Baker's house in Swampscott, Mass., on Oct. 14, 2020. The Centers for Disease Control and Prevention has extended a moratorium on evictions until the end of July.; Credit: Michael Dwyer/AP

The Centers for Disease Control and Prevention has extended a moratorium on evictions until the end of July. The ban had been set to expire next week, raising concerns that there could be a flood of evictions with some seven million tenants currently behind on their rent.

The Biden administration says the extension is for "one final month" and will allow time for it to take other steps to stabilize housing for those facing eviction and foreclosure. The White House says it is encouraging state and local courts to adopt anti-eviction diversion programs to help delinquent tenants stay housed and avoid legal action.

The federal government will also try to speed up distribution of tens of billions of dollars in emergency rental assistance that's available but has yet to be spent. In addition, a moratorium on foreclosures involving federally backed mortgages has been extended for "a final month," until July 31.

In announcing the extension of the eviction moratorium, the CDC said that the COVID-19 "pandemic has presented a historic threat to the nation's public health. Keeping people in their homes and out of crowded or congregate settings — like homeless shelters — by preventing evictions is a key step in helping to stop the spread of COVID-19."

The CDC first issued the moratorium last September. It was extended once already in March, until June 30.

But landlords have been pushing back, arguing that they've taken a huge financial hit over the past year, losing billions of dollars a month in rent. Several business groups have sued the CDC and won, though court decisions to lift the moratorium have been stayed pending appeal.

The Alabama Association of Realtors, which brought one of the cases, argued that the CDC exceeded its authority in issuing the ban. The group is seeking relief from the U.S. Supreme Court, but the justices have yet to respond.

In its petition, the Realtors association called the CDC's "continued insistence that public-health concerns necessitate that landlords continue to provide free housing for tenants who have received vaccines (or passed up the chance to get them)...sheer doublespeak."

Housing advocates have argued that the moratorium is still very much needed. They note that $46 billion in emergency rental assistance approved by Congress has been slow getting into the hands of those it was intended to help. The money is supposed to cover rent that tenants currently owe.

The National Low Income Housing Coalition reports that in some states, less than five percent of the funds have been distributed so far. The group pushed the administration to extend the ban to give states and localities more time to get the money out.

Despite the moratorium, thousands of renters have still faced the threat of eviction because of loopholes in the law. Many are the lowest income tenants and disproportionately people of color. A new study by the Eviction Lab at Princeton University has found that communities with the lowest vaccination rates tend to have the highest eviction filings, raising additional health concerns.

"Allowing the moratorium to expire before vaccination rates increase in marginalized communities could lead to increased spread of, and deaths from, COVID-19," a group of more than 40 House lawmakers wrote in a letter this week to President Biden and CDC Director Rochelle Walensky, urging them to extend the moratorium.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Patrick Doherty volunteered for a new medical intervention of gene-editor infusions for the treatment of genetically-based diseases.; Credit: /Patrick Doherty

Patrick Doherty had always been very active. He trekked the Himalayas and hiked trails in Spain.

But about a year and a half ago, he noticed pins and needles in his fingers and toes. His feet got cold. And then he started getting out of breath any time he walked his dog up the hills of County Donegal in Ireland where he lives.

"I noticed on some of the larger hill climbs I was getting a bit breathless," says Doherty, 65. "So I realized something was wrong."

Doherty found out he had a rare, but devastating inherited disease — known as transthyretin amyloidosis — that had killed his father. A misshapen protein was building up in his body, destroying important tissues, such as nerves in his hands and feet and his heart.

Doherty had watched others get crippled and die difficult deaths from amyloidosis.

"It's terrible prognosis," Doherty says. "This is a condition that deteriorates very rapidly. It's just dreadful."

So Doherty was thrilled when he found out that doctors were testing a new way to try to treat amyloidosis. The approach used a revolutionary gene-editing technique called CRISPR, which allows scientists to make very precise changes in DNA.

"I thought: Fantastic. I jumped at the opportunity," Doherty says.

On Saturday, researchers reported the first data indicating that the experimental treatment worked, causing levels of the destructive protein to plummet in Doherty's body and the bodies of five other patients treated with the approach.

"I feel fantastic," Doherty says. "It's just phenomenal."

The advance is being hailed not just for amyloidosis patients but also as a proof-of-concept that CRISPR could be used to treat many other, much more common diseases. It's a new way of using the innovative technology.

"This is a major milestone for patients," says Jennifer Doudna of the University of California, Berkeley, who shared a Nobel Prize for her work helping develop CRISPR.

"While these are early data, they show us that we can overcome one of the biggest challenges with applying CRISPR clinically so far, which is being able to deliver it systemically and get it to the right place," Doudna says.

CRISPR has already been shown to help patients suffering from the devastating blood disorders sickle cell disease and beta thalassemia. And doctors are trying to use it to treat cancer and to restore vision to people blinded by a rare genetic disorder.

But those experiments involve taking cells out of the body, editing them in the lab, and infusing them back in or injecting CRISPR directly into cells that need fixing.

The study Doherty volunteered for is the first in which doctors are simply infusing the gene-editor directly into patients and letting it find its own way to the right gene in the right cells. In this case, it's cells in the liver making the destructive protein.

"This is the first example in which CRISPR-Cas9 is injected directly into the bloodstream — in other words systemic administration — where we use it as a way to reach a tissue that's far away from the site of injection and very specifically use it to edit disease-causing genes," says John Leonard, the CEO of Intellia Therapeutics, which is sponsoring the study.

Doctors infused billions of microscopic structures known as nanoparticles carrying genetic instructions for the CRISPR gene-editor into four patients in London and two in New Zealand. The nanoparticles were absorbed by their livers, where they unleashed armies of CRISPR gene-editors. The CRISPR editor honed in on the target gene in the liver and sliced it, disabling production of the destructive protein.

Within weeks, the levels of protein causing the disease plummeted. Researchers reported at the Peripheral Nerve Society Annual Meeting and in a paper published in The New England Journal of Medicine.

"It really is exciting," says Dr. Julian Gillmore, who is leading the study at the University College London, Royal Free Hospital.

"This has the potential to completely revolutionize the outcome for these patients who have lived with this disease in their family for many generations. It's decimated some families that I've been looking after. So this is amazing," Gillmore says.

The patients will have to be followed longer, and more patients will have to be treated, to make sure the treatment's safe, and determine how much it's helping, Gillmore stresses. But the approach could help those struck by amyloidosis that isn't inherited, which is a far more common version of the disease, he says.

Moreover, the promising results potentially open the door for using the same approach to treatment of many other, more common diseases for which taking cells out of the body or directly injecting CRISPR isn't realistic, including heart disease, muscular dystrophy and brain diseases such as Alzheimer's.

"This is really opening a new era as we think about gene-editing where we can begin to think about accessing all kinds of different tissue in the body via systemic administration," Leonard says.

Other scientists who are not involved in the research agree.

"This is a wonderful day for the future of gene-editing as a medicine,"
agree Fyodor Urnov, a professor of genetics at the University of California, Berkeley. "We as a species are watching this remarkable new show called: our gene-edited future."

Doherty says he started feeling better within weeks of the treatment and has continued to improve in the weeks since then.

"I definitely feel better," he told NPR. "I'm speaking to you from upstairs in our house. I climbed stairs to get up here. I would have been feeling breathless. I'm thrilled."

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: /Rose Wong for NPR/KHN

Claire Lang-Ree was in a lab coat taking a college chemistry class remotely in the kitchen of her Colorado Springs, Colo., home, when a profound pain twisted into her lower abdomen. She called her mom, Jen Lang-Ree, a nurse practitioner who worried it was appendicitis and found a nearby hospital in the family's health insurance network.

After a long wait in the emergency room of Penrose Hospital, Claire received morphine and an anti-nausea medication delivered through an IV. She also underwent a CT scan of her abdomen and a series of tests.

Hospital staffers ruled out appendicitis and surmised Claire was suffering from a ruptured ovarian cyst, which can be a harmless part of the menstrual cycle but can also be problematic and painful. After a few days — and a chemistry exam taken through gritted teeth — the pain went away.

Then the bill came.

Patient: Claire Lang-Ree, a 21-year-old Stanford University student who was living in Colorado for a few months while taking classes remotely. She's insured by Anthem Blue Cross through her mom's work as a pediatric nurse practitioner in Northern California.

Total Bill: $18,735.93, including two $722.50 fees for a nurse to "push" drugs into her IV, a process that takes seconds. Anthem's negotiated charges were $6,999 for the total treatment. Anthem paid $5,578.30, and the Lang-Rees owed $1,270.45 to the hospital, plus additional bills for radiologists and other care. (Claire also anted up a $150 copay at the ER.)

Service Provider: Penrose Hospital in Colorado Springs, part of the regional health care network Centura Health.

What Gives: As hospitals disaggregate charges for services once included in an ER visit, a hospitalization or a surgical procedure, there has been a proliferation of newfangled fees to increase billing. In the health field, this is called "unbundling." It's analogous to the airlines now charging extra for each checked bag or for an exit row seat. Over time, in the medical industry, this has led to separate fees for ever-smaller components of care. A charge to put medicine into a patient's IV line — a "push fee" — is one of them.

Though the biggest charge on Claire's bill, $9,885.73, was for a CT scan, in many ways Claire and her mom found the push fees most galling. (Note to readers: Scans are frequently many times more expensive when ordered in an ER than in other settings.)

"That was so ridiculous," says Claire, who adds she had previously taken the anti-nausea drug they gave her; it's available in tablet form for the price of a cup of coffee, no IV necessary. "It works really well. Why wasn't that an option?"

In Colorado, the average charge for the code corresponding to Claire's first IV push has nearly tripled since 2014, and the dollars hospitals actually get for the procedure has doubled. In Colorado Springs specifically, the cost for IV pushes rose even more sharply than it did statewide.

A typical nurse in Colorado Springs makes about $35 an hour. At that rate, it would take nearly 21 hours to earn the amount of money Penrose charged for a push of plunger that likely took seconds or at most minutes.

The hospital's charge for just one "IV push" was more than Claire's portion of the monthly rent in the home she shared with roommates. In the end, Anthem did not pay the push fees in its negotiated payment. But claims data shows that in 2020 Penrose typically received upward of $1,000 for the first IV push. And patients who didn't have an insurer to dismiss such charges would be stuck with them. Colorado hospitals on average received $723 for the same code, according to the claims database.

"It's insane the variation that we see in prices, and there's no rhyme or reason," says Cari Frank with the Center for Improving Value in Health Care, a Colorado nonprofit that runs a statewide health care claims database. "It's just that they've been able to negotiate those prices with the insurance company and the insurance company has decided to pay it."

To put the total cost in context, Penrose initially charged more money for Claire's visit than the typical Colorado hospital would have charged for helping someone give birth, according to data published by the Colorado Division of Insurance.

Even with the negotiated rate, "it was only $1,000 less than an average payment for having a baby," Frank says.

In an email statement, Centura said it "conducted a thorough review and determined all charges were accurate" and went on to explain that "an Emergency Room (ER) must be prepared for anything and everything that comes through the doors," requiring highly trained staff, plus equipment and supplies. "All of this adds up to large operating costs and can translate into patient responsibility."

As researchers have found, little stands in the way of hospitals charging through the roof, especially in a place like an emergency room, where a patient has few choices. A report from National Nurses United found that hospital markups have more than doubled since 1999, according to data from the United States Bureau of Labor Statistics. In an email, Anthem called the trend of increasing hospital prices "alarming" and "unsustainable."

But Ge Bai, an associate professor of accounting and health policy at Johns Hopkins University, says when patients see big bills it isn't only the hospital's doing — a lot depends on the insurer, too. For one, the negotiated price depends on the negotiating power of the payer, in this case, Anthem.

"Most insurance companies don't have comparable negotiating or bargaining power with the hospital," said Bai. Prices in a state like Michigan, where Bai said the UAW union covers a big proportion of Michigan patients, will look very different from those in Colorado.

Also, insurers are not the wallet defenders patients might assume them to be.

"In many cases, insurance companies don't negotiate as aggressively as they can, because they earn profit from the percentage of the claims," she says. The more expensive the actual payment is, the more money they get to extract.

Though Anthem negotiated away the push fees, it paid the hospital 30% more than the average Level IV emergency department visit in Colorado that year, and it paid quadruple what Medicare would allow for her CT scan.

Resolution: Claire and her mom decided to fight the bill, writing letters to the hospital and searching for information on what the procedures should have cost. The cost of the IV pushes and CT scan infuriated them — the hospital wanted more than double for a CT than what top-rated hospitals typically charged in 2019.

But the threat of collections wore them out and ultimately they paid their assigned share of the bill — $1,420.45, which was mostly coinsurance.

"Eventually it got to the point where I was like, 'I don't really want to go to collections, because this might ruin my credit score,'" says Claire, who didn't want to graduate from college with dinged credit.

Bai and Frank say the state of Maryland can provide a useful benchmark for medical bills, since it sets the prices that hospitals can charge for each procedure. Data provided by the Maryland Health Care Commission shows that Anthem and Claire paid seven times what she likely would have paid for the CT scan there, and nearly 10 times what they likely would have paid for the emergency department Level IV visit. In Maryland, intravenous pushes typically cost about $200 apiece in 2019. A typical Maryland hospital would have received only about $1,350 from a visit like Claire's, and the Lang-Rees would have been on the hook for about $270.

Claire's pain has come back a few times, but never as bad as that night in Colorado. She has avoided reentering an emergency room since then. After visiting multiple specialists back home in California, she learned she might have had a condition called ovarian torsion.

The Takeaway: Even at an in-network facility and with good insurance, patients can get hurt financially by visiting the ER. A few helpful documents can help guide the way to fighting such charges. The first is an itemized bill.

"I just think it's wrong in the U.S. to charge so much," says Jen Lang-Ree. "It's just a little side passion of mine to look at those and make sure I'm not being scammed."

Bai, of Johns Hopkins, suggests asking for an itemized explanation of benefits from the insurance company, too. That will show what the hospital actually received for each procedure.

Find out if the hospital massively overcharged. The Medicare price lookup tool can be useful for getting a benchmark. And publicly available data on health claims in Colorado and at least 17 other states can help, too.

Vincent Plymell with the Colorado Division of Insurance encourages patients to reach out if something on a bill looks sketchy. "Even if it's not a plan we regulate," he wrote in an email, departments such as his "can always arm the consumer with info."

Finally, make scrutinizing such charges fun. Claire and Jen made bill-fighting their mother-daughter hobby for the winter. They recommend pretzel chips and cocktails to boost the mood.

Bill of the Month is a crowdsourced investigation by KHN and NPR that dissects and explains medical bills. Do you have an interesting medical bill you want to share with us? Tell us about it!

This content is from Southern California Public Radio. View the original story at SCPR.org.

Moderna says recently completed studies have found its vaccine to have a neutralizing effect against all COVID-19 variants tested, including the delta variant.; Credit: Fred Tanneau/AFP via Getty Images

Studies have found that Moderna's COVID-19 vaccine is effective against several variants of concern, including the delta variant, the biotech company announced.

Moderna said Tuesday that recently completed studies have found the vaccine to have a neutralizing effect against all COVID-19 variants tested, including the beta, delta, eta and kappa variants.

While still highly effective against the delta variant, the study showed the vaccine was less effective against it and certain other variants than against the original strain of the virus.

The antibody response against the delta variant was about two times weaker than against the ancestral strain of the virus.

The news echoes other findings that the Moderna and Pfizer vaccines are highly effective against the delta variant. A study published this month in Nature found that Pfizer's vaccine was able to neutralize variants including delta, though at somewhat reduced strength.

"These new data are encouraging and reinforce our belief that the Moderna COVID-19 Vaccine should remain protective against newly detected variants," Stéphane Bancel, Moderna's chief executive officer, said in a statement. "These findings highlight the importance of continuing to vaccinate populations with an effective primary series vaccine."

The company also said it is developing a booster candidate: a 50-50 mix of its currently authorized COVID-19 vaccine and another messenger RNA vaccine it has developed.

The delta variant is spreading fast

The delta variant is the fast-moving form of the coronavirus that is now found in 96 countries, including the United States.

Last week, Dr. Anthony Fauci of the National Institutes of Health said the delta variant is "currently the greatest threat in the U.S. to our attempt to eliminate COVID-19," noting that the proportion of infections being caused by the variant is doubling every two weeks.

The delta variant is now infecting at least 1 out of every 5 people who get the virus in the United States. In some sections of the country, the variant is already far more common, particularly in parts of the Midwest and West. At its current pace, the delta variant is expected to be the dominant virus in the U.S. within weeks.

Dr. Maria Van Kerkhove, an infectious disease expert at the World Health Organization, called the delta variant "incredibly transmissible."

"These viruses are becoming more fit. The virus is evolving, and this is natural," she told NPR's Morning Edition. "It's more transmissible than the alpha variant, so we need to just do all we can to prevent as many infections as we can and do what we can do to reduce the spread."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Advocates for expanding Medicaid in Kansas staged a protest outside the entrance to the statehouse parking garage in Topeka in May 2019. Today, twelve states have still not expanded Medicaid. The biggest are Texas, Florida, and Georgia, but there are a few outside the South, including Wyoming and Kansas.; Credit: John Hanna/AP

There are more than 2 million people across the United States who have no option when it comes to health insurance. They're in what's known as the "coverage gap" — they don't qualify for Medicaid in their state, and make too little money to be eligible for subsidized health plans on the Affordable Care Act insurance exchanges.

Briana Wright is one of those people. She's 27, lives near Jackson, Miss., works at McDonalds, and doesn't have health insurance. So to figure out her options when she recently learned she needed to have surgery to remove her gallbladder, she called Health Help Mississippi, a nonprofit that helps people enroll in health insurances.

Because she lives in Mississippi, "I wasn't going to be eligible for Medicaid — because I don't have children [and] I'm not pregnant," she tells NPR. When she had her income checked for Healthcare.gov, it was just shy of the federal poverty line — the minimum to qualify for subsidies. "It was $74 [short]. I was like, oh wow," she says.

Wright's inability to get a subsidized policy on Healthcare.gov is related to how the Affordable Care Act was originally designed. People needing insurance who were above the poverty line were supposed to be funneled via the federal and state insurance exchanges to private policies — with federal subsidies to help make those policies affordable. People who were under the poverty line were to be funneled to a newly-expanded version of Medicaid — the public health insurance program that is jointly funded by states and the federal government. But the Supreme Court made Medicaid expansion essentially optional in 2012, and many Republican-led states declined to expand. Today, there are 12 holdout states that have not expanded Medicaid, and Mississippi is one of them.

So, Wright is still uninsured. Her gallbladder is causing her pain, but she can't afford the surgery without shuffling household bills, and risking leaving something else unpaid. "I'm stressed out about it. I don't know what I'm going to do," she says. "I'm going to just have to pay it out of pocket or get on some payment plan until it all gets paid for."

Hoping to finally find a fix for Wright and the millions like her who are in Medicaid limbo, several teams of Democratic lawmakers have recently been hashing out several options — hoping to build on the momentum of the latest Supreme Court confirmation that the ACA is here to stay.

OPTION 1: Sweet-talk the 12 holdout states

The COVID-19 relief bill passed in March included financial enticements for these 12 states to expand Medicaid. Essentially, the federal government will cover 90% of the costs of the newly eligible population, and an additional 5% of the costs of those already enrolled.

It's a good financial deal. An analysis by the nonprofit Kaiser Family Foundation estimates that the net benefit for these states would be $9.6 billion. But, so far — publicly, at least — no states have indicated they intend to take the federal government up on its offer.

"If that is not getting states to move, then that suggests that the deep root of their hesitation is not about financial constraint," says Jamila Michener, a professor of government at Cornell University and author of the book Fragmented Democracy: Medicaid Federalism And Unequal Politics.

Instead, Michener says, the reluctance among some Republican-led legislatures and governors to expand Medicaid may be a combination of partisan resistance to President Obama's signature health law, and not believing "this kind of government intervention for these groups of people is appropriate."

What's Next: When asked about progress on this front in an April press briefing, Biden's press secretary Jen Psaki said "the President is certainly supportive of — and an advocate for — states expanding Medicaid," but did not answer a follow up about whether the White House was directly reaching out to governors regarding this option.

OPTION 2: Create a federal public option to fill the gap

Some have advocated for circumventing these holdout states and creating a new, standalone federal Medicaid program that people who fall into this coverage gap could join. It would be kind of like a tailored public option just for this group.

This idea was included in Biden's 2022 budget, which says, in part: "In States that have not expanded Medicaid, the President has proposed extending coverage to millions of people by providing premium-free, Medicaid-like coverage through a Federal public option, paired with financial incentives to ensure States maintain their existing expansions."

But it wouldn't be simple. "That can be quite complex — to implement a federal program that's targeted to just these 2.2 million people across a handful of states," says Robin Rudowitz, co-director of the Medicaid program at the Kaiser Family Foundation, who wrote a recent analysis of the policy options.

It also may be a heavy lift, politically, says Michener. "Anything that expanded the footprint of the federal government and its role in subsidizing health care would be especially challenging," she says.

What's next: This idea was raised as a possible solution in a letter last month from Georgia's Democratic senators to Senate leaders, and Sen. Raphael Warnock said this week he plans to introduce legislation soon.

OPTION 3: Get around stubborn states by letting cities expand Medicaid

Instead of centralizing the approach, this next idea goes even more local. The COVER Now Act, introduced by Rep. Lloyd Doggett, D-Texas, would empower local jurisdictions to expand Medicaid. So, if you live in Austin, Texas, maybe you could get Medicaid, even if someone in Lubbock still couldn't.

The political and logistical challenges would be tough, policy analysts say. Logistically, such a plan would require counties and cities to create new infrastructure to run a Medicaid program, Rudowitz notes, and the federal government would have to oversee how well these new local programs complied with all of Medicaid's rules.

"It does not seem feasible politically," Michener says. "The legislators who would have to vote to make this possible would be ceding quite a bit of power to localities." It also might amplify geographic equity concerns, she says. People's access to health insurance would not just "be arbitrarily based on what state you live in — which is the current state of affairs — It's also going to be arbitrary based on what county you live in, based on what city you live in."

What's next: Doggett introduced the bill earlier this month. There's no guarantee it would get a vote on the House floor and — even if it did — it wouldn't survive a likely filibuster in the evenly divided Senate.

OPTION 4: Change the ACA to open up the exchanges

A fourth idea, Rudowitz says, is to change the law to remove the minimum cutoff for the private health insurance exchanges, since "right now, individuals who are below poverty are not eligible for subsidies in the marketplace." With this option, states wouldn't be paying any of the costs, since the federal government pays premium subsidies, Rudowitz says, but "there are issues around beneficiary protections, benefits, out-of-pocket costs."

What's next: This idea hasn't yet been included in any current congressional bills.

Will any of these ideas come to fruition?

Even with a variety of ideas on the table, "there's no slam dunk option, it's a tough policy issue," Rudowitz says. All of these would be complicated to pull off.

It's possible Democrats will include one of these ideas in a reconciliation bill that could pass without the threat of a Republican filibuster. But that bill has yet to be written, and what will be included is anyone's guess.

Even so, Michener says she's glad the discussion of the Medicaid coverage gap is happening, because it's sensitizing the public, as well as people in power, to the problem and potentially changing the political dynamic down the line. "Even in policy areas where you don't have any kind of guaranteed victory, it is often worth fighting the fight," she says. "Politics is a long game."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Many hospitals around the country, including Medstar Washington Hospital in Washington DC., have started sharing their prices online in compliance with a recent federal rule.; Credit: DANIEL SLIM/AFP via Getty Images

A colonoscopy might cost you or your insurer a few hundred dollars — or several thousand, depending on which hospital or insurer you use.

Long hidden, such price variations are supposed to be available in stark black and white under a Trump administration price transparency rule that took effect at the start of this year. It requires hospitals to post a range of actual prices — everything from the rates they offer cash-paying customers to costs negotiated with insurers.

Many have complied.

But some hospitals bury the data deep on their websites or have not included all the categories of prices required, according to industry analysts. A sizable minority of hospitals have not disclosed the information at all.

While imperfect and potentially of limited use right now to the average consumer, the disclosures that are available illustrate the huge differences in prices — nationally, regionally and within the same hospital. But they're challenging for consumers and employers to use, giving a boost to a cottage industry that analyzes the data.

While it's still an unanswered question whether price transparency will lead to overall lower prices, KHN took a dive into the initial trove of data to see what it reveals. Here are five takeaways from the newly public data and tips for how you might be able to use it to your benefit

1) As expected, prices are all over the map

The idea behind the requirement to release prices is that the transparency may prompt consumers to shop around, weighing cost and quality. Perhaps they could save a few hundred dollars by getting their surgery or imaging test across town instead of at the nearby clinic or hospital.

Under the Trump-era rule, hospitals must post what they accept from all insurers for thousands of line items, including each drug, procedure or treatment they provide. In addition, hospitals must present this in a format easily readable by computers and include a consumer-friendly separate listing of 300 "shoppable" services, bundling the full price a hospital accepts for a given treatment, such as having a baby or getting a hip replacement.

The negotiated rates now being posted publicly often show an individual hospital accepting a wide range of prices for the same service, depending on the insurer, often based on how much negotiating power each has in a market.

In some cases, the cash-only price is less than what insurers pay. And prices may vary widely within the same city or region.

In Virginia, for example, the average price of a diagnostic colonoscopy is $2,763, but the range across the state is from $208 to $10,563, according to a database aggregated by San Diego-based Turquoise Health, one of the new firms looking to market the data to businesses, while offering some information free of charge to patients.

2) Patients can look up the information, but it's incomplete

Patients can try to find the price information themselves by searching hospital websites, but even locating the correct tab on a hospital's website is tricky.

Typically, consumers don't comparison-shop, preferring to choose convenience or the provider their doctor recommends. A recent Peterson-KFF Health System Tracker brief, for instance, found that 85% of adults said they had not researched online the price of a hospital treatment.

And hospitals say the transparency push alone won't help consumers much, because each patient's situation is different and may vary from the average— and individual deductibles and insurance plans complicate matters.

But if you do want to try, here's one tip: "You can Google the hospital name and the words 'price transparency' and see where that takes you," says Caitlin Sheetz, director and head of analytics at the consulting firm ADVI Health in the Washington, D.C., metro area.

Typing in "MedStar Health hospital transparency," for example, likely points to the MedStar Washington Hospital Center's "price transparency disclosure" page, with a link to its full list of prices, as well as its separate list of 300 shoppable services.

By clicking on the list of shoppable services, consumers can download an Excel file. Searching it for "colonoscopy" pulls up several variations of the procedure, along with prices for different insurers, such as Aetna and Cigna, but a "not available" designation for the cash-only price. The file explains that MedStar does not have a standard cash price but makes determinations case by case.

Performing the same Google search for the nearby Inova health system results in less useful information.

Inova's website links to a long list of thousands of charges, which are not the discounts negotiated by insurers, and the list is not easily searchable. The website advises those who are not Inova patients or who would like to create their own estimate to log into the hospitals' "My Chart" system, but a search on that for "colonoscopy" failed to produce any data.

3) Third-party firms are trying to make searching prices simpler – and cash in

Because of the difficulty of navigating these websites — or locating the negotiated prices once there — some consumers may turn to sites like Turquoise. Another such firm is Health Cost Labs, which will have pricing information for 2,300 hospitals in its database when it goes live July 1.

Doing a similar search for "colonoscopy" on Turquoise shows the prices at MedStar by insurer, but the process is still complicated. First, a consumer must select the "health system" button from the website's menu of options, click on "surgical procedures," then click again on "digestive" to get to it.

There is no similar information for Inova because the hospital has not yet made its data accessible in a computer-friendly format, said Chris Severn, CEO of Turquoise.

Inova spokesperson Tracy Connell said in a written statement that the health system will create personalized estimates for patients and is "currently working to post information on negotiated prices and discounts on services."

Firms like Turquoise and Health Cost Labs aim to sell the data gathered from hospitals nationally to insurers, employers and others. In turn, those groups may use it in negotiations with hospitals over future prices. While that may drive down prices in areas with a lot of competition, it might do the opposite where there are few hospitals to choose from, or in situations where a hospital raises its prices to match competitors.

4) Consumers could use this data to negotiate, especially if they're paying cash

For consumers who go the distance and can find price data from their hospitals, it may prove helpful in certain situations:

• Patients who are paying cash or who have unmet deductibles may want to compare prices among hospitals to see if driving farther could save them money.
• Uninsured patients could ask the hospital for the cash price or attempt to negotiate for the lowest amount the facility accepts from insurers.
• Insured patients who get a bill for out-of-network care may find the information helpful because it could empower them to negotiate a discount off the hospitals' gross charges for that care.

While there's no guarantee of success, "if you are uninsured or out of network, you could point to some of those prices and say, 'That's what I want,'" says Barak Richman, a contract law expert and professor of law at Duke University School of Law.

But the data may not help insured patients who notice their prices are higher than those negotiated by other insurers.

In those cases, legal experts say the insured patients are unlikely to get a bill changed because they have a contract with that insurer, which has negotiated the price with their contracted hospitals.

"Legally, a contract is a contract," says Mark Hall, a health law professor at Wake Forest University.

Richman agrees.

"You can't say, 'Well, you charged that person less,'" he notes, but neither can they say they'll charge you more.

Getting the data, however, relies on the hospital having posted it.

5) Hospitals still aren't really on board

When it comes to compliance, "we're seeing the range of the spectrum," says Jeffrey Leibach, a partner at the consulting firm Guidehouse, which found earlier this year that about 60% of 1,000 hospitals surveyed had posted at least some data, but 30% had reported nothing at all.

Many in the hospital industry have long fought transparency efforts, even filing a lawsuit seeking to block the new rule. The suit was dismissed by a federal judge last year.

They argue the rule is unclear and overly burdensome. Additionally, hospitals haven't wanted their prices exposed, knowing that competitors might then adjust theirs, or health plans could demand lower rates. Conversely, lower-cost hospitals might decide to raise prices to match competitors.

The rule stems from requirements in the Affordable Care Act. The Obama administration required hospitals to post their chargemaster rates, which are less useful because they are generally inflated, hospital-set amounts that are almost never what is actually paid.

Insurers and hospitals are also bracing for next year when even more data is set to come online. Insurers will be required to post negotiated prices for medical care across a broader range of facilities, including clinics and doctors' offices.

In May, the Centers for Medicare & Medicaid Services sent letters to some of the hospitals that have not complied, giving them 90 days to do so or potentially face penalties, including a $300-a-day fine.

"A lot of members say until hospitals are fully compliant, our ability to use the data is limited," says Shawn Gremminger, director of health policy at the Purchaser Business Group on Health, a coalition of large employers.

His group and others have called for increasing the penalty for noncomplying hospitals from $300 a day to $300 a bed per day, so "the fine would be bigger as the hospital gets bigger," Gremminger says. "That's the kind of thing they take seriously."

Already, though, employers or insurers are eyeing the hospital data as leverage in negotiations, says Severn, Turquoise's CEO. Conversely, some employers may use it to fire their insurers if the rates they're paying are substantially more than those agreed to by other carriers.

"It will piss off anyone who is overpaying for health care, which happens for various reasons," he says.

KHN (Kaiser Health News) is a national newsroom that produces in-depth journalism about health issues. Together with Policy Analysis and Polling, KHN is one of the three major operating programs at KFF (Kaiser Family Foundation).

This content is from Southern California Public Radio. View the original story at SCPR.org.

People rest while riding a Los Angeles Metro Rail train amid the coronavirus pandemic on April 1, 2020 in Los Angeles, California.; Credit: Mario Tama/Getty Images

Despite the racial reckoning going on in America right now, and despite the fact that attitudes towards race, inclusion and representation are different now than they were 30 years ago, new research from UC Berkeley shows that a large majority of American metro areas are more segregated now than they were in 1990. The new report from Berkeley’s Institute covers a number of topic areas, but among the key findings were from the national segregation report component of the project, which found Los Angeles to be the sixth-most segregated metro area with more than 200,000 people.

Today on AirTalk, we’ll talk with the lead researcher on the new report and a local historian to talk about how we see the findings of the report play out in Southern California.

Guests:

Stephen Menendian, assistant director and director of research at the Othering & Belonging Institute at UC Berkeley, which works to identify and eliminate the barriers to an inclusive, just, and sustainable society in order to create transformative change; he tweets @SMenendian

Eric Avila, professor of history, urban planning, and Chicano/a studies at UCLA

This content is from Southern California Public Radio. View the original story at SCPR.org.

Bill Cosby exits the Montgomery County Courthouse in Norristown, Pa., Saturday, June 17, 2017. ; Credit: Matt Rourke/AP

Pennsylvania’s highest court overturned. Bill Cosby’s sex assault conviction Wednesday after finding an agreement with a previous prosecutor prevented him from being charged in the case.

Cosby has served more than two years of a three- to 10-year sentence at a state prison near Philadelphia. He had vowed to serve all 10 years rather than acknowledge any remorse over the 2004 encounter with accuser Andrea Constand.

We dive into how this all happened, through the lens of law, celebrity and the MeToo movement. 

With files from the Associated Press

Guests: 

Ambrosio Rodriguez, former prosecutor; he is currently a criminal defense attorney at The Rodriguez Law Group in Los Angeles; he led the sex crimes team and was in the homicide unit in the Riverside D.A.’s office; he tweets at @aer_attorney

Laurie L. Levenson, professor of criminal law at Loyola Law School in Los Angeles and former federal prosecutor

This content is from Southern California Public Radio. View the original story at SCPR.org.

Sherman Institute, built in the Mission Revival architectural style, enrolled its first students on Sept. 9, 1902.; Credit: SHERMAN INDIAN MUSEUM

Earlier this month, Secretary of the Interior Deb Haaland announced an effort to search federal boarding schools for burial sites of Native American kids. 

The effort is similar to the one in Canada, which found the remains of up to 751 people, likely mostly children, at an unmarked grave in a defunct school in the province of Saskatchewan.  

We dive into the history of American Indian Boarding Schools, as well as their evolution and what the schools that still exist, including Sherman Institute High School in California, look like today.

Guests:

Brenda Child, professor of American Studies and American Indian Studies at the University of Minnesota; she is the author of many books, including “Boarding School Seasons: American Indian Families, 1900-1940” (University of Nebraska Press, 2000)

Amanda Wixon, curator at the Sherman Indian Museum, which is on the campus of Sherman Indian High School; assistant curator at Autry museum of the American West; PhD candidate in history at UC Riverside where her research is in Native American history, especially federal boarding schools and the carceral aspects of the Sherman Institute

This content is from Southern California Public Radio. View the original story at SCPR.org.

Facemasks remain worn as firefighter paramedic Jorge Miranda, holding syringe, speaks with Eduardo Vasquez, who has lived homeless on the streets of Los Angeles since 1992, before administering the one-shot Johnson and Johnson' Janssen Covid-19 vaccine as part of outreach to the homeless by members of the Los Angeles Fire Department's Covid Outreach unit on June 14, 2021 in Los Angeles.; Credit: FREDERIC J. BROWN/AFP via Getty Images

In our continuing series looking at the latest medical research and news on COVID-19, Larry Mantle speaks with UCSF’s Dr. Peter Chin-Hong. 

Topics today include:

• Two weeks after reopening, LA County’s new COVID-19 cases have doubled

• CDC: Infected vaccinated people carry less COVID-19 virus

• Delta variant is now detected in all 50 states

• J&J: “At present, there is no evidence to suggest need for a booster dose to be administered”

• Novavax claims vaccine’s overall efficacy is 89.7%

• Another respiratory virus is spreading in the U.S.

• Curevac’s final trial show shot is far less effective than other vaccines

• Can we now live with the coronavirus?

• Israel scrambles to curb rising COVID-19 infection rates

• Is it time to rethink “one-size-fits-all” approach for masking?

Guest:

Peter Chin-Hong, M.D., infectious disease specialist and professor of medicine at the UCSF Medical Center; he tweets @PCH_SF

This content is from Southern California Public Radio. View the original story at SCPR.org.

A homeless encampment is pictured at Venice Beach, on June 30, 2021 in Venice, California, where an initiative began this week offering people in homeless encampments a voluntary path to permanent housing.; Credit: FREDERIC J. BROWN/AFP via Getty Images

The majority of unhoused women across the nation — 57% according to recent data — say domestic violence is the direct cause of losing their permanent home. 

In L.A, almost 40% of women who are homeless say they’ve experienced abuse in the last 12 months.

The choice they’ve been forced to make: Stay in danger with their abusers — or escape, with nowhere to go.

“It’s like jumping from a burning building but there’s no net to catch you,” said Nikki Brown, a survivor and advocate.

There are many, complex reasons why survivors become homeless. Shame is one of them. Yet studies show that one in three women experience some form of intimate partner abuse in their lives. So why don’t we talk about it more?

“It's the greatest secret that's super common and nobody wants to admit it,” said Brown. “There are so many complicated circumstances that make it really hard to leave. And when you can't leave, that element of shame and blame is the thing that makes it so hard to talk about.”

Today on AirTalk, we’re learning more about reporter Julia Paskin’s series Pushed Out, on domestic violence and homelessness in Los Angeles. Do you have an experience you want to share? Give us a call at 866-893-5722.

Guests:

Julia Paskin, KPCC producer and reporter who created the “Pushed Out” series; she tweets @JuliaPaskinInc

Amy Turk, CEO of Downtown Women’s Center, which advocates and offers services for women experiencing homelessness and formerly homeless women; she tweets @AmyFTurk

Nikki Brown, staff attorney at Community Legal Aid SoCal, where she has clients that are domestic violence survivors

This content is from Southern California Public Radio. View the original story at SCPR.org.